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Endothelial cells (ECs) are polarised, allowing them to secrete different proteins into 
both the circulating fluid, and the underlying matrix. However, there is little 
understanding of how this polarised secretion occurs. Using mass spectrometry, I 
have examined the role liprin-α1 plays in the secretion of proteins, which had 
previously been identified to be involved in the secretion of fibronectin from the 
basolateral surface. I have shown that liprin-α1 affects the polarised secretion of a 
subset of proteins, particularly those involved in the assembly of the extracellular 
matrix (ECM) such as collagen-α1 and α2. Previous studies have suggested that 
atorvastatin treatment has a positive pleiotropic effect upon ECs, reducing the risk of 
atherosclerosis. I have shown that atorvastatin treatment affected the secretion of 
certain proteins from both the apical and basolateral surface of the ECs. One major 
group of proteins affected were proteins involved in the ECM. Dysregulation of the 
ECM has previously been shown to be involved in the pathogenesis of atherosclerosis. 
Additionally, atorvastatin treatment increased the apical/basal secretion ratio of some 
proteins also known to be involved in the pathogenesis of atherosclerosis, including 
biglycan. However, atorvastatin also increased the apical secretion of protein-
glutamine gamma-glutamyltransferase 2, which is known to decrease rupture of 
atherosclerotic plaques. Whilst my study provides a slight insight into the polarised 
secretion from ECs and the role atorvastatin treatment may have in patients with 
atherosclerosis, further research is needed to validate these results. 
   
iii 
 
Dedication and Acknowledgements 
 
Firstly, I would like to thank my supervisor Professor Harry Mellor for his assistance, guidance 
and patience throughout my project. I would also like to express my gratitude to Dr 
Ananthalakshmy Sundararaman and Dr Haoche Wei for their support throughout my project, 
for teaching me new techniques, and providing suggestions and insights to allow me to 
develop as an individual scientist. I would like to especially extend my thanks to Haoche for 
generously spending his time assisting me with my initial experiments, and Ananthalakshmy 
for her assistance during imaging. I would also like to acknowledge the Wolfson Bioimaging 
Facility at the University of Bristol for access to the microscopes used throughout my project. 
I would like to pay special regards to my family for supporting me throughout my entire study, 
and whom without none of this would be possible. They have given an enormous amount of 
time and dedication towards my education, and their encouragement has enabled to finish my 
study. I would like to thank my sister Anna for providing criticisms and feedback on my draft 
versions. 
I would like to thank my friends for their constant support, and the University of Bristol 















I declare that the work in this dissertation was carried out in accordance with the 
requirements of the University's Regulations and Code of Practice for Research Degree 
Programmes and that it has not been submitted for any other academic award. Except 
where indicated by specific reference in the text, the work is the candidate's own work. Work 
done in collaboration with, or with the assistance of, others, is indicated as such. Any views 





Page of Contents 
 
 
Abstract ..................................................................................................................... ii 
Dedication and Acknowledgements ...................................................................... iii 
Authors declaration ................................................................................................ iv 
Page of Contents ...................................................................................................... v 
List of Tables ......................................................................................................... viii 
List of Figures ......................................................................................................... ix 
Chapter 1 Endothelial cells ..................................................................................... 1 
1.1 Endothelial Cell Functions ................................................................................. 2 
1.1.1 Transport ..................................................................................................... 2 
1.1.1.1 Glucose................................................................................................. 2 
1.1.1.2 Amino acids .......................................................................................... 3 
1.1.1.3 Albumin ................................................................................................ 4 
1.1.2 Secretion..................................................................................................... 6 
1.1.2.1 Extracellular matrix proteins ................................................................. 6 
1.1.2.2 Coagulation factors ............................................................................... 8 
1.1.2.3 Nitric oxide .......................................................................................... 10 
1.1.2.4 Inflammatory mediators ...................................................................... 10 
1.2 The Vascular System ...................................................................................... 12 
1.2.1 The cardiovascular system ....................................................................... 12 
1.2.1.1 Arteries ............................................................................................... 12 
1.2.1.2 Microvasculature ................................................................................ 15 
1.2.1.3 Veins .................................................................................................. 17 
1.2.2 Lymphatic system ..................................................................................... 19 
1.3 Endothelial cell subtypes................................................................................. 22 
1.3.1 Specific differences between endothelial cells .......................................... 22 
1.3.1.1 Continuous endothelium in the blood-brain-barrier ............................. 22 
1.3.1.2 Discontinuous endothelium in the liver ............................................... 23 
1.3.1.3 Fenestration endothelium in the kidney .............................................. 24 
1.3.2 Mechanisms of endothelial cell heterogeneity .......................................... 25 
1.4 Secretory Pathway .......................................................................................... 27 
1.4.1 Epithelial secretion .................................................................................... 27 
vi 
 
1.4.2 Extracellular vesicles ................................................................................ 31 
1.4.2.1 Exosomes ........................................................................................... 31 
1.4.2.2 Microvesicles ...................................................................................... 33 
1.4.3 Endothelial cell secretion .......................................................................... 34 
1.4.4 Polarised EC secretion ............................................................................. 37 
1.5 Statins ............................................................................................................. 40 
1.6 Aims of Project ................................................................................................ 41 
Chapter 2 Materials and Methods ......................................................................... 42 
2.1 Reagents ......................................................................................................... 42 
2.1.1 Cell Culture ............................................................................................... 42 
2.1.2 General reagents ...................................................................................... 42 
2.1.3 General solutions and buffers ................................................................... 43 
2.1.4 Antibodies ................................................................................................. 43 
2.1.5 siRNA oligonucleotides ............................................................................. 44 
2.1.6 Statins ....................................................................................................... 44 
2.2 Cell Biology ..................................................................................................... 45 
2.2.1 Mammalian cell culture ............................................................................. 45 
2.2.2 Coating of tissue culture dishes ................................................................ 45 
2.3 Biochemistry ................................................................................................... 46 
2.3.1 Preparation of materials ............................................................................ 46 
2.3.1.1 siRNA transfection .............................................................................. 46 
2.3.1.2 Statin preparation ............................................................................... 46 
2.3.2 Western Blotting ....................................................................................... 46 
2.3.2.1 Sample preparation ............................................................................ 46 
2.3.2.2 Sodium-dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) ............................................................................................................ 47 
2.3.2.3 Western blotting.................................................................................. 47 
2.3.3 Permeability assay .................................................................................... 48 
2.3.3.1 siRNA Transwell culture ..................................................................... 48 
2.3.3.2 Statin Transwell Culture ..................................................................... 48 
2.3.3.3 Addition of FITC-dextran .................................................................... 48 
2.3.4 Mass spectrometry ................................................................................... 49 
2.3.4.1 Mass spectrometry ............................................................................. 49 
2.3.4.2 Proteomic analysis ............................................................................. 49 
2.3.5 ELISA ....................................................................................................... 50 
vii 
 
2.3.6 Immunofluorescence microscopy ............................................................. 50 
2.4 Statistical analysis ........................................................................................... 51 
Chapter 3 The HUVEC polarised secretome ........................................................ 52 
3.1 Introduction ..................................................................................................... 52 
3.2 Results ............................................................................................................ 54 
3.2.1 Analysis of the HUVEC secreted proteome .............................................. 54 
3.2.2 Transfection of HUVEC with Liprin-α1 siRNA can affect monolayer 
permeability ....................................................................................................... 57 
3.2.3 Liprin-α1 controls the sorting of a subset of proteins to the basolateral 
surface ............................................................................................................... 59 
3.2.4 Liprin-α1 siRNA transfection of HUVEC does not affect the distribution of 
EDA-FN when analysed using mass spectrometry ............................................ 65 
3.3 Conclusion ................................................................................................... 69 
Chapter 4 Effect of statin treatment on HUVEC ................................................... 73 
4.1 Introduction ..................................................................................................... 73 
4.2 Results ............................................................................................................ 75 
4.2.1 Measurement of the effect of statins on endothelial permeability ............. 75 
4.2.2 Optimisation of atorvastatin treatment for mass spectrometry .................. 78 
4.2.3 Atorvastatin treatment generally causes an increase of the 
apical/basolateral secretion ratio compared to the control ................................. 84 
4.2.4 Treatment with atorvastatin....................................................................... 90 
4.3 Conclusion .................................................................................................... 105 
Chapter 5 Future Directions ................................................................................ 107 













List of Tables 
 
Table    Description Page no. 
2.1  Mammalian cell line 42 
2.2 Cell culture media type 42 
2.3 Reagents 42 
2.4 Solution/Buffers 43 
2.5 Primary Antibodies 43 
2.6 Secondary Antibodies 43 
2.7 siRNA oligonucleotides 44 
2.8 Statins 44 
2.9 siRNA transfection 46 
2.10 SDS-Page gel 45 
3.1 Polarised secretion Apical < Basal 54 
3.2 Polarised secretion Apical > Basal 54 
3.3 HUVEC significant secreted proteins 56 




List of Figures 
 
Figure Description Page No. 
1.1 Albumin transcytosis across the endothelial cell 5 
1.2 Arrangement of the basement membrane 7 
1.3 Structure of blood vessels 13 
1.4 Types of capillaries 16 
1.5 Valves within lymphatic vessels 20 
1.6 Release of microvesicles and exosomes 32 
1.7 Release of vWF from endothelial cells 35 
3.1 Analysis of the HUVEC secreted proteome 55 
3.2 HUVEC display polarised secretion 56 
3.3 Function of proteins in the HUVEC secretome 58 
3.4 Method of obtaining permeability data 60 
3.5 Liprin-α1 siRNA can affect HUVEC monolayer 61 
3.6 Liprin-α1 localises to focal adhesions, by binding directly to 
the β1 tail of integrins 
63 
3.7 Liprin-α1 affects the polarised secretion of fibronectin from the 
basolateral surface 
64 
3.8 Liprin-α1 siRNA affects the polarised secretion of certain 
proteins 
66 
3.9 Liprin-α1 has no effect on the secretion and distribution of 
EDA fibronectin 
68 
4.1 Addition of simvastatin has no effect on HUVEC cell:cell 
junctions  
76 
4.2 Atorvastatin disrupts cell junctions at high concentrations 78 
4.3 Low concentrations of simvastatin have no significant effect 
on HUVEC cell:cell junctions 
80 
4.4 Low concentrations of atorvastatin have no significant effect 
on HUVEC cell:cell junctions 
81 
4.5 Atorvastatin has no significant effect on HUVEC cell:cell 




4.6 The total protein abundance was higher at 5 nM basolateral 
than any other condition 
84 
4.7 Total protein abundance at 5 nM atorvastatin is considerably 
different to any other protein abundance 
86 
4.8 The apical/basolateral secreted ratio of 15 nM and 50 nM 
atorvastatin total mass spectrometry proteins differs to to 
control ratio 
87 
4.9 The apical/basolateral ratio of known secreted proteins 
generally increases with atorvastatin treatment compared to 
the control 
88 
4.10 Function of proteins in the HUVEC atorvastatin secretome 90 
4.11 Total secretion of certain proteins increases with atorvastatin 
treatment 
92 
4.12 Apical secretion of certain proteins noticeably increases, 
whilst basal level decreases slightly with atorvastatin 
treatment 
94 
4.13 Apical secretion of collagen α-1 increases with atorvastatin 
treatment, whilst basal secretion decreases 
97 
4.14 Apical secretion of certain proteins increases, whilst basal 
level decreases with atorvastatin treatment 
98,99 
4.15 Apical secretion of macrophage migration inhibitory factor 
remains steady, whilst basal secretion noticeably changes 





List of Abbreviations 
 
Abbreviation Description 
ATP Adenosine triphosphate 
AJ Adherens junction 
BBB Blood brain barrier 
BSA Bovine serum albumin 
CCV Clathrin coated vesicle 
EE  Early endosome 
EC Endothelial cell 
EDA-FN Extra domain A fibronectin 
eNOS Endothelial nitric oxide synthase 
ECM Extracellular matrix 
EV Extracellular vesicle 
tPA Fibrinolytic tissue-type plasminogen activator  
FN Fibronectin 
GLUT1 Glucose transporter 1 
HUVEC Human umbilical vein endothelial cell 
IGF Insulin-like growth factor 
IL-8 Interleukin 8 
ICAM-1 Intracellular adhesion molecule-1 
ILV Intraluminal vesicles 
LSEC Liver sinusoidal endothelial cells 
LDL Low density lipoprotein 
MV Microvesicle 
MVB Multivesicular bodies 
MVE Multivesicular endosome 
NO Nitric oxide 
NOS Nitric oxide synthase 
TSP1 Thrombospondin-1 
TJ  Tight junction 
TGN Trans-Golgi network 
VE-cadherin Vascular endothelial cadherin 
vWF Von Willebrand factor 
wPB Weibel-Palade bodies 
ZO-1 Zona occludens 1 
1 
 
Chapter 1 Endothelial cells 
 
Endothelial cells (ECs) line the internal surface of the vessels within the circulatory system, 
forming a thin layer called the endothelium. Initially thought to be an inert barrier, this dynamic 
layer of cells acts as a selectively permeable barrier, regulating the passage of molecules 
between the tissue and the blood or lymph stream [1]. These vessels form part of the human 
vascular system, which facilitate the transportation of blood and lymph around the body and 
are involved in the removal of waste substances such as CO2, to maintain homeostasis, the 
maintenance of a constant internal environment. Within the human body there are 
approximately 1013  ECs, making up 1.25% of the average human body mass [1]. 
There are three main types of vessels within the vascular system: veins, arteries, and 
capillaries. ECs play important roles in supporting the integrity of these vessels which are each 
specialised to accommodate a variety of pressures and the particular demands of individual 
tissues [2]. Dependent on their location within the body, ECs within the vascular system have 
distinctive morphology and functions and can display different surface receptors, allowing 
them to respond to the same stimulus in different ways [1]. ECs lining larger vessels appear 
to be thicker and more continuous in comparison to the endothelial layer of capillaries, which 
are thinner and often have small openings within the cells called fenestrations, which allow 
rapid exchange of molecules between the tissue and the blood [3]. Surprisingly, heterogeneity 
of the ECs also occurs between cells in the same environment, meaning they can respond 
differently to the same signal [4]. 
The endothelium has multiple mechanisms that allow it to regulate its environment, as well as 
responding to external stresses, by methods such as controlling the transfer of oxygen and 
nutrients, secreting angiocrine factors and controlling vascular tone [5]. The endothelium plays 
an important role in regulating blood flow, and the ECs are able to change their surface 
depending on the circumstances, for example, in the case of injury ECs are able to express 
pro-coagulant molecules upon their surface to prevent excessive blood loss [6]. They can 
react in response to pathological situations such as inflammation, as well as being able to 
secrete vasoactive substances, which control the constriction of the blood vessel [7]. 
ECs act as a dynamic organ within the body, with mechanisms to regulate blood flow, control 
the movement of fluid, ions and other molecules between the blood and underlying tissue, as 
well as playing a critical role in repairing the vessel after vascular injury [6]. Dysregulation of 
these finely controlled processes can result in clinical disorders, such as excessive bleeding 
due to the low level of release of the clotting proteins by the ECs [8]. 
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One of the most important functions of the endothelium is regulating transport across the 
vascular endothelial barrier [9]. Under normal conditions the endothelium acts as an 
impermeable barrier, requiring specialist mechanisms to transport solutes into the cell and the 
underlying tissue, to allow them to produce ATP and perform other essential processes. The 
endothelium is critical in facilitating the transportation of nutrients to tissues, and the removal 
of waste. This exchange can occur by both transcellular mechanisms, such as via specialist 
channels, and paracellular mechanisms via the intracellular junctions [9]. Some ECs require 
higher levels of transport regulation than others, such as in those within the blood brain barrier 
(BBB). In the BBB, there is an extremely low level of transcytosis of solutes, and the tight 
junctions between ECs strongly limit the paracellular flux of solutes in comparison with other 
ECs in other locations within the body [10].  
  
1.1.1.1 Glucose  
 
The endothelium is a metabolically active barrier and produces essential molecules for 
specialist ECs functions, such as angiogenesis. In order to produce these molecules the ECs 
require ATP, which can be produced through the metabolism of glucose, which is transported 
around the body via the circulating blood [11]. Whilst small molecules such as oxygen can 
diffuse through the plasma membrane of ECs, larger molecules require specific transport 
proteins. These transport proteins exist in both the luminal and abluminal membrane of ECs, 
allowing glucose and other nutrients to be transported from the blood through the ECs, for use 
by the parenchymal cells [12]. 
Transportation of glucose into the cell occurs by facilitated diffusion via the glucose transporter 
isoform GLUT1, which is present in the plasma membrane of the EC [1]. GLUT1 is ubiquitous 
between all cell types, but is expressed most highly within the endothelium of the blood brain 
barrier (BBB) [11]. The BBB is a highly impermeable barrier formed of ECs which prevent 
neurotoxins from entering the brain. ECs within the BBB have a large number of mitochondria 
which use the glucose to produce ATP, which is needed for the highly regulated transport 
mechanisms to transport ions into the ECs [13]. Defective transport of glucose across the 
blood-brain barrier and into the brain parenchyma is associated with developmental delay and 
infantile seizures, due to the reduced amount of glucose available to the brain, and the limited 
ability of the brain to use other fuels [14].  
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There is suggestion that GLUT4, another isoform of GLUT transporter is present within ECs, 
but evidence is still unclear. GLUT4 is an insulin regulated transporter, most commonly found 
within adipose tissue and striated muscle, however GLUT4 has also been shown to be in the 
brain microvascular endothelium [15]. It is suggested that this is the only vascular location 
where GLUT4 occurs, as it has not been shown to be expressed in any other vascular cells 
[15]. 
 
1.1.1.2 Amino acids  
 
There are multiple transport systems that allow the influx of amino acids across the plasma 
membrane in ECs, where they can be used for fuels for oxidative phosphorylation [11]. In the 
absence of glucose, the normal fuel source for ECs, amino acids including ʟ-glutamate and ʟ-
glutamine are rapidly oxidised to be used as an alternative fuel source [11]. When ʟ-glutamine 
is absent, EC proliferation is impaired [16]. 
The amino acid ʟ-arginine is required for the production of nitic oxide (NO), which is 
continuously synthesised by ECs [17]. NO is then released from the endothelium as a gas or 
attached to other molecules, and stimulates the production of cyclic guanosine 
monophosphate (cGMP) [17]. Smooth muscle cells within the vessel wall are affected by NO, 
and the subsequent production of cGMP. When NO is secreted to the underlying smooth 
muscle, the production of cGMP causes the relaxation of the smooth muscle cells, affecting 
the resistance of the blood vessel, and lowering blood pressure [17]. The production of NO 
can change rapidly in response to physiological changes, allowing the ECs to exert control 
over the vascular tone, and has been shown to be atheroprotective [16,17]. 
Within ECs, there are both Na+-dependent and Na+-independent amino acid transporters that 
mediate the transport of amino acids. The charge on the amino acid governs which transporter 
the amino acid will use. B0,+ is an Na+ -dependent amino acid transporter, which is highly 
specific for cationic amino acids, which the Na+-independent transporters y+, y+L, b0,+, b+, are 
able to transport both cationic and neutral amino acids [11]. The amino acid ʟ-arginine is 
transported into the ECs via the y+ cationic amino acid transporter [1]. 
The principal amino acid transport system is y+L system, which is involved in the Na+-
independent uptake of dibasic amino acids such as arginine and lysine [18]. The y+L system 
is also capable of transporting neutral amino acids, but this process is mostly Na+-dependent 
[18]. Other systems, such as the B0,+ system have broad substrate specificity, also favour 
particular amino acids, such as the neutral leucine and isoleucine over other zwitterionic and 
cationic amino acids [18]. By being Na+-dependent, the B0,+ system can form gradients of its 
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preferred substances, and change the magnitudes of these with changes in the Na+ and K+ 
system [18]. 
Like glucose transporters, amino acid transporters are also located upon the abluminal surface 
of ECs, to allow the transcellular passage of the amino acids. In the BBB, where little passive 
transport of polar solutes can occur, there are high levels of specific transport proteins that 
regulate the passage of amino acids between the brain interstitial fluid and the blood [19].  
Together, these transport mechanisms allow for effective amino acid transport, the importance 
of which is shown by the decrease in EC proliferation in the absence of ʟ-glutamine, and the 




Within the human body, serum albumin is the most abundant circulating plasma protein, with 
the liver producing about 10-15g per day [20]. Albumin is a soluble protein that is involved in 
the transport of hydrophobic substances such as steroids through the blood, and maintains 
the oncotic pressure; the pull of fluid from the interstitial space into the vessel (Figure 1.1) [21]. 
Once albumin enters the circulatory system from the liver around 35% of the albumin remains 
in the blood stream, and the remainder enters the tissue space, where it later returns to the 
circulation via the lymphatic system.  
Albumin is a negatively charged protein that has multiple ligand binding sites, and is able to 
bind and carry small hydrophobic molecules, including endogenous and exogenous 
substances such as cholesterol and drugs respectively, across the vascular endothelium from 
the intravascular to the extravascular space (Figure 1.1) [20,22]. Albumin is able to affect the 
activity and half-life of drugs such as ibuprofen, as the drug binds to albumin, reducing the 
rate of clearance [23].  
Albumin cannot easily pass through the endothelial layer as it is too large, but instead attaches 
to the cell membrane surface. The plasma membrane of the EC then invaginates, which then 
buds off to form intracellular vesicles called caveolae [22]. Albumin is transcytosed within the 
cell, allowing the transport of molecules across the interior of the cell, from the luminal to the 
abluminal space, where it can be secreted (Figure 1.1). Within caveolae there is a specific 
albumin binding protein called gp60, that is selectively expressed on the plasma membrane 
of continuous endothelium [24]. Unlike other substances endocytosed by the caveolae, 
albumin internalisation by gp60 has been shown to result in transcytosis (Figure 1.1) [24]. 

















Figure 1.1 Albumin transcytosis across the endothelial cell. The albumin bound gp60 
receptor is internalised from the apical plasma membrane using the scaffolding protein 
caveolin-1. The albumin:gp60 complex is transcytosed in caveolae carriers across the 
endothelial cell, and the albumin is subsequently released from the basolateral membrane 
into the tissue. Adapted from  Impact of albumin on drug delivery – New applications on the 












the brain where it could damage neuronal tissue by inducing neuronal hyperactivity, and 





To perform their essential function, ECs secrete a multitude of different factors, both into the 
luminal space and into the tissue. The polarisation of ECs is maintained by the tight junctions, 
allowing ECs to secrete different factors and different concentrations of factors, from both their 
apical and basolateral surface. Whilst the importance of EC secretion to support their function 
is well known, there are few studies into the secreted EC proteome, and the mechanisms that 
allow for the secretion to occur. 
 
1.1.2.1 Extracellular matrix proteins 
 
The ECM is the non-cellular component within all tissues and organs, composed of a cross-
linked network of extracellular components including collagen, fibronectin and glycoproteins 
[26]. The ECM provides a structural scaffold for the ECs providing structural support for the 
cells to grow upon, as well as modulating the cell’s biochemical and biophysical behaviours 
[26]. Through interactions between the EC and integrins, the ECM provides an essential 
scaffold for maintaining the organisation of ECs into blood vessels, as well as being essential 
for the survival of the ECs.  
The ECM underlying the ECs within a tissue consists of a basement membrane, and an 
interstitial matrix that is present between the cells. ECs are responsible for the synthesis and 
formation of the basal lamina, the primary layer of the basement membrane on which the 
endothelium sits (Figure 1.2).  
The main protein component within the basal lamina is collagen IV, a subtype of the collagen 
family, which provides structural and tensile strength to the ECM [27]. The high tensile strength 
of collagen is due the triple helical structure of collagen, formed by three intertwined 
superhelices which contain one or more regions with the characteristic Gly-X-Y repeat, where 
X and Y can be any amino acid [27,28]. By the transition to the triple helix, collagen has higher 
rigidity and becomes less accessible to proteases, increasing its stability [27]. These 
characteristics allow collagen IV to form a network which acts as a scaffold, which can tether 
















Figure 1.2 Arrangement of the basement membrane. Adapted from Vitamin A 
Deficiency and Alterations in the Extracellular Matrix, Barber et al., Nutrients; published by 
MDPI (2014) [232].  
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glycoproteins secreted by ECs, and also play a role in cell migration and adhesion, and are 
important for the survival of tissues [29]. Laminin provides the interaction between the EC and 
the basement membrane, by being anchored via transmembrane linkers called integrins at 
the cell surface [30]. Laminins also interact with other secreted components of the cellular 
matrix, including the glycoproteins nidogen and perlecan, which act to stabilise the ECM, and 
form cross links between components (Figure 1.2) [31]. The integrins present upon ECs, 
specifically the α1β1 and α2β1 integrins also bind collagen IV through specific sites within the 
collagen IV heterotrimer [32].  
Another protein which forms part of the ECM is fibronectin, which is mainly secreted from the 
basolateral surface of the EC. Fibronectins are a class of glycoproteins that are present in two 
forms; a soluble form present in blood plasma, and insoluble present within the ECM [33]. ECs 
synthesise fibronectin, which is transported as dimers to the basolateral surface where it is 
secreted. Fibronectin is then polymerised and incorporated into the ECM. Fibronectin binds to 




 of the EC, anchoring the cell to the ECM, and also to 
other ECM proteins such as collagen, creating a net to provide structural and biochemical 
support for the ECs (Figure 1.2) [34]. Previous studies have shown that fibronectin is 
predominantly polarised to the basolateral surface of ECs, in line with it playing such an 
integral role there [35]. 
Together these proteins form a stable network for the ECs to survive upon. The production of 
these proteins by the EC is highly regulated to prevent pathological conditions such as liver 
cirrhosis, where increased levels of deposition of collagen IV by liver sinusoidal ECs is 
clinically significant [36].  
 
1.1.2.2 Coagulation factors 
 
In healthy endothelium the luminal surface is both anti-coagulant and anti-thrombotic to 
prevent the attachment of cells and clotting proteins [6]. ECs are also able to secrete a 
multitude of factors which are involved in the regulation of haemostasis; encompassing the 
processes that control blood clotting, the activation of platelets, and vascular repair [6,37]. 
When vascular injury occurs, rapid pro-inflammatory and wound healing responses are 
triggered to repair the vessel and prevent blood loss. In healthy tissue, the endothelium 
expresses various anticoagulants upon its surface, such as thrombomodulin and heparin, to 
maintain the normal flow of blood [6]. However, when injury to the vessel occurs, the ECs 
become activated and the underlying cells, such as the smooth muscle cells, are exposed [6].  
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ECs synthesise and secrete the pro-coagulant von Willebrand Factor (vWF), a glycoprotein 
which can bind the coagulation Factor VIII which is involved in the activation of Factor Xa in 
the clotting cascade [38]. vWF is secreted from both the apical surface into the circulating fluid 
and from the basolateral surface into the extracellular matrix [39]. vWF secretion by ECs  
occurs via two pathways, one which occurs constitutively, and another triggered by exocytosis 
from Weibel-Palade bodies, which store vWF within the EC [40].  
When the endothelial layer is damaged, the underlying collagen is also exposed to the blood, 
which initiates the adhesion of circulating platelets via the vWF in ECM to the exposed 
collagen, creating a platelet aggregate to stem blood loss [39]. Activated ECs and the smooth 
muscle cells express the integral membrane protein Tissue Factor (TF); which can bind the 
freely circulating serine protease Factor VII , which initiates the subsequent activation of other 
serine protease factors present within the blood, including Factor Xa [6]. Factor Xa is able to 
combine with another serine protease called Factor Va to proteolytically cleave the circulating 
coagulation factor prothrombin to form thrombin [41]. Thrombin is then able to catalyse the 
production of fibrin from fibrinogen, which is able to form a cross-linked fibrin mesh [41]. This 
cross-linked fibrin mesh, along with the platelet aggerate is able to form a stable clot, acting 
to plug the injury and prevent blood loss [6]. 
The EC surface normally expresses protease activated receptors (PAR), which initiate a 
cascade of cell signals upon activation by proteases such as thrombin, Factor Xa and 
TF:Factor VIIa complex [6]. The activation of PAR-1 by thrombin induces the activation of 
Weibel-Palade bodies, causing the release of vWF and Tissue Plasminogen Activator (t-PA) 
from the EC, as well as regulating the surface exposure of TF and triggering the release of 
NO from ECs, which inhibits platelet activation [40]. Once the wound is repaired, dissolution 
of the clot is activated by fibrinolytic agents such as t-PA, which catalyses the degradation of 
fibrin within the clot [6]. 
Under normal conditions, the secretion of vWF into the plasma is constitutive, but during acute 
bacterial, viral or parasitic infection secretion of vWF can increase seven-fold [40]. High levels 
of vWF may be an indirect indicator of atherosclerosis [42]. vWF disease is a genetic disease 
that results in low levels of, or non-functional vWF, of which symptoms include heavy bleeding 
due to the inability to clot [43]. 
To maintain ‘normal’ blood flow, ECs express anticoagulants upon their surface, including 
thrombomodulin (TM), and heparin-like proteoglycans, and secrete platelet inhibitors such as 
nitric oxide (NO) [6].  TM binds thrombin and acts as a cofactor to activate protein C; a vitamin 
K-dependent glycoprotein [44]. In studies where TM was mutated, there was limited activation 
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of protein C, which was shown to lead to a hypercoagulable state [45]. Protein C deficiency 
can result in clinical conditions including thrombus formation [46]. 
By secretion of these factors, the endothelium can maintain the blood in a non-coagulative 
state and can respond to changes, such as vessel damage, to secrete the required factors. 
Damage to the endothelium, such as the formation of plaques may prevent the EC from being 
able to regulate coagulation successfully and may contribute to the formation of a thrombus 
[6]. Certain diseases, including the mentioned vWF disease and protein C deficiency, are just 
an example of the important role the endothelium plays.  
 
1.1.2.3 Nitric oxide 
 
One of the roles of the endothelium is to regulate vascular tone, which it does via the 
production and secretion of vasoactive substances. The endothelium produces potent 
mediators, including NO, prostacyclin and endothelin, which are released from the EC in 
response to stimuli [1]. NO is a powerful vasodilator and is produced constitutively under 
normal conditions by type III NO synthase (eNOS), the NO synthase present within ECs.  
Endothelial nitric oxide synthase (eNOS) works constitutively to produce NO. Certain chemical 
substances are able to alter the production of NO. When vascular injury occurs, ECs become 
activated, producing adhesion molecules and recruiting inflammatory cells resulting in the 
release of cytokines [47]. The release of cytokines causes increased production of NO by 
eNOS, and the cytokine inducible NOS; type II NOS [1]. NO produced by ECs can diffuse 
across the interstitial space to the smooth muscle, where it activates the enzyme guanylate 
cyclase which facilitates the conversion of GTP to cGMP, which indirectly leads to the 
inhibition of calcium influx into the cell [1]. This leads to the decrease in smooth muscle tension 
due to decreased phosphorylation of myosin light chains, causing vasodilation [1,47]. NO 
secretion also results in the inhibition of platelet aggregating, as well as inducing expression 
of chemokines and adhesion molecules on the vascular surface of ECs, and has antioxidant 
properties [48] . 
 
1.1.2.4 Inflammatory mediators 
 
Under normal conditions the endothelium is non-thrombogenic, controls the flow of blood and 
the passage of proteins from the blood, and inhibits inflammation [49]. However, during events 
such as infection, the endothelium must respond to pro-inflammatory signals such as 
interleukin 1. This causes the ECs to become activated, and undergo specific changes needed 
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for its function in the inflammatory response [50]. During changes including the upregulation 
of surface antigens and adhesion molecules, and the modification of the EC surface to a 
prothrombotic phenotype, ECs are able to react to and produce cytokines, and other 
inflammatory mediators [50]. 
One chemokine produced by ECs is IL-8, a neutrophil chemotactic factor. Within the EC, IL-8 
is stored within Weibel-Palade bodies along with vWF and t-PA, and is also released upon 
PAR-1 activation by proteases such as thrombin [51]. The role of IL-8 within the inflammatory 
response is to attract neutrophils towards the site of the infection, where the neutrophils can 
then enter the tissue to reach the affected site [50]. IL-8 has also been shown to stimulate 
proliferation and migration of ECs in vivo [1]. Other members of the interleukin family produced 
by ECs include IL-1 and IL-6 [52]. IL-1 has been shown to be involved with platelet activation, 
and stimulating the production of NO from ECs, as well as inducing the production of other 
chemokines by ECs, and can stimulate the release of IL-8 [52].  
Other cytokines secreted by ECs include colony stimulating factors (CSF) and growth factors. 
CSFs are glycoproteins that cause the proliferation and differentiation of haematopoietic stem 
cells into macrophages or granulocytes, which are both types of white blood cells involved in 
the inflammatory response [53]. Growth related oncogene-alpha (GRO-α) is another 
neutrophil attractant released by ECs, and has also been shown to be proangiogenic [52].  
As well as secreting these cytokines, ECs also change their surface during the inflammatory 
response, such as expressing E-selectin and intercellular adhesion molecule-1 (ICAM-1), 
which mediate the adhesion of leucocytes to the ECs [1]. Another adhesion molecule released 












1.2 The Vascular System 
 
The vascular system, also referred to as the circulatory system, is responsible for the transport 
of blood and lymph throughout the body. These fluids are carried through vessels which are 
specially adapted, dependent on their location within the vascular system. Blood is transported 
through the cardiovascular system by three major vessels; arteries, veins and capillaries, 
which form a continuous network throughout the body. Lymph vessels carry lymph fluid that 
has been absorbed from tissues and returns the fluid to the cardiovascular system. The 
innermost surface of these vessels consists of ECs, which in veins and arteries form a 
continuous sheet due to tight intercellular adhesion molecules such as vascular endothelial 
cadherin (VE-cadherin) and zonula occludens 1 (ZO-1). However, in lymphatic vessels and 
some capillaries the endothelium is discontinuous which increases its permeability, increasing 
the transport of solutes between the vessel and the surrounding tissue. The cardiovascular 
and lymphatic systems work together to maintain homeostasis, the stable equilibrium of 
physiological processes.  
 
1.2.1 The cardiovascular system 
 
As previously stated, the cardiovascular system consists mainly of arteries, veins, and 
capillaries. Each of these vessels are structurally similar consisting of ECs surrounded by a 
basal lamina, and have varying amounts of connective tissue, elastic fibres and smooth 
muscle cells in their surrounding layers [55]. Blood vessels are typically made up of three 
individual layers, the tunica intima, the innermost layer of the vessel directly in contact with 
the blood; the tunica media, the layer underlying the tunica intima; and the tunica adventitia, 
the outermost layer (Figure 1.3) [56]. The composition of these layers differs between vessels, 




Arteries generally carry oxygen-rich blood from the heart to deliver it throughout the body. 
There are two exceptions to this; the pulmonary artery, which carries blood away from the 
heart towards the lungs where it becomes oxygenated; and the umbilical artery that carries 
deoxygenated blood out from the foetus. After the oxygenated blood has returned from the 
lungs, it enters the left ventricle of the heart. The contraction of the heart, called systole, 
pushes the blood out of the left ventricle of the heart through the aortic valve where it enters  
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Figure 1.3. Structure of blood vessels. A) Capillaries are the smallest of the blood 
vessels, and their wall consists of a single layer of endothelial cells. B) Arteries have a thick 
tunica media made up of smooth muscles and elastic fibres, and a thick outer wall. Their 
lumen is lined by a layer of endothelial cells C) Veins are the largest of the blood vessels, 
and their tunica media consists of a thin layer of smooth muscle and elastic fibres and 
surrounded by a thinner outer wall. Veins have the largest lumen, which is also lined with 
endothelial cells. Adapted from Engineering biofunctional in vitro vessel models using a 
multilayer bioprinting technique, Schöneberg et al, Scientific Reports; published by Nature 






the aorta, before branching into large arteries [57].  The relaxation of the heart, called diastole, 
causes the aortic valve to close preventing backflow. Artery walls are specially adapted to 
cope with this initial high-pressure during systole and low-pressure during diastole to maintain 
constant pressure within the blood, by having thick artery walls which contain elastin. During 
systole the increase of pressure causes the artery walls to stretch, before recoiling during 
diastole. The elasticity of arteries results in the Windkessel effect, damping the fluctuations in 
blood pressure throughout systole and diastole, allowing an almost constant blood pressure 
[58,59]. 
There are two main subtypes of arteries within the body; elastic and muscular [56]. The 
arteries closest to the heart, including the pulmonary artery and the aorta are both elastic 
arteries, and contain more elastin and collagen within their tunica media than the muscular 
vessels, which are responsible for the distribution of blood to the smaller arteries within the 
body (Figure 1.3)  [60]. The elastic arteries are closest to the heart and receive the highest 
pressured blood, and this increased elastin and collagen allows them to maintain a relatively 
constant pressure despite the constant pumping of the heart [60]. Muscular arteries, medium 
sized arteries which the blood enters after passing through the elastic arteries, contain fewer 
elastic fibres and more smooth muscle cells in their tunica media than elastic arteries (Figure 
1.3) [56]. The increased number of smooth muscle cells allow the vascular tone to be 
controlled by the release of NO and other vasoactive molecules, to control and maintain blood 
flow and pressure [61]. The arterial system contains about 10-15% of the total blood volume. 
After the blood has passed through the muscular arteries, it then enters into smaller vessels 
of the arterial system, called arterioles [62]. This branching causes the blood pressure to drop 
as the blood is transported throughout the body, due to the cumulative increase in vessel 
diameter as more branching occurs. Arterioles are blood vessels of between 8 and 60 
micrometres, only have one to two layers of smooth muscle within their tunica media, and a 
thinner tunica externa than other artery types [62]. These arterioles then branch into 
metarterioles, which provides the link between arterioles and capillaries; the vessels which 
carry blood through the tissues. Unlike other vessels within the arterial system, metarterioles 
do not have a continuous tunica media; but instead the smooth muscle forms rings at the 
entrance of capillaries [56]. These rings of smooth muscle tightly regulate the blood flow into 
the capillaries, and open when the surrounding tissues require oxygen and the removal of 
waste.  
On the innermost lining of all these vessels are ECs. In comparison to ECs in other vessels, 
arterial ECs are generally thicker, and have tighter intercellular junctions [61]. Arterial ECs are 
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also longer and narrower than other vessels, aligning with the direction of the blood flow within 
the vessels [61].  
Dysfunction of the arterial ECs, characterised by a shift in ECs towards reduced vasodilation, 
a proinflammatory state and prothrombic properties is associated with most forms of 
cardiovascular disease, including atherosclerosis [63]. The formation of an atherosclerotic 
plaque most commonly occurs within the coronary artery, but can occur within any artery within 
the cardiovascular system [64]. There are multiple risk factors for atherosclerosis, including 
high blood cholesterol, high blood pressure and smoking [65]. These factors can cause 
damage to the endothelial layer, causing ECs to secrete vasoconstrictive factors including 
ET-1, as well as factors which cause the proliferation of smooth muscle cells [66]. The 
secretion of these factors causes a chemotactic effect on leukocytes and platelets, causes of 
the overexpression of cellular adhesion molecules such as ICAM-1 on the EC surface and the 
secretion of inflammatory cytokines [66]. The expression of these adhesion molecules allows 
leukocytes to adhere to the EC surface, where they can then migrate into the tunica intima. 
Inflammatory cytokines cause the EC to secrete IL-1, causing the accumulation of neutrophils 
which produce reactive oxygen species which further damage the endothelium [66].  
These processes lead to the formation of an atherosclerotic plaque, containing ECM 
components, cholesterol, and cellular debris within the artery wall. Over time this plaque can 
build up, leading to narrowing of the artery which can cause devastating conditions, including 
occlusion of the artery, which could cause a myocardial infarction (heart attack) and strokes. 
Damaged ECs also have an impaired release of NO causing the vessel to become overly 
permeable, which contributes to the progression of atherosclerosis  [66].  
 
1.2.1.2 Microvasculature  
 
After the blood has passed through the arterioles, the vascular system branches further 
forming a network of capillary vessels. Capillaries are vessels which have a radius of about 2-
5 µM, and their wall consists of a single sheet of ECs, with a small amount of basal lamina 
and contractile cells called pericytes; which have a variety of functions including regulating 
blood flow (Figure 1.3). Networks of capillaries are present throughout tissues, supplying them 
with oxygen and nutrients and removing waste products including CO2.  
There are three types of blood capillaries: continuous, fenestrated and discontinuous. 
Dependent on the location and function of the capillary within the body, capillaries are present 
as one of these three types [67]. Continuous capillaries are formed of a continuous layer of 
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Figure 1.4. Types of capillaries. A) Endothelial cells in continuous capillaries are joined 
continuously to each other by junctional proteins, with no openings in the monolayer of 
basement membrane. Examples of tissues include the central nervous system B) 
Endothelial cells in fenestrated capillaries have fenestrations between cells, which are 
covered by a permeable diaphragm, and have a continuous basement membrane. Example 
tissues include the gastrointestinal tract. C) Discontinuous capillaries have large gaps 
between endothelial cells, and a discontinuous or absent basement membrane. Example 
tissues include the liver. Adapted from Organotypic vasculature: From descriptive 








permeability barrier to unwanted solutes, and form capillary networks within muscles and the 
brain, as well as other organs. Fenestrated capillaries also have a continuous basement 
membrane, but also contain fenestrations within the ECs which are about 60-70 nm in 
diameter [67]. These fenestrations are covered by a diaphragm, a layer of fibrils that can open 
to allow the passage of larger molecules (Figure 1.4B). These capillaries are found within 
tissues with extensive molecular exchange, such as the kidney. Discontinuous ECs, also 
known as sinusoidal ECs, contain openings within capillaries of around 30-40 µM in diameter 
between ECs. These ECs, which are present in the organs including the liver and the spleen, 
have a discontinuous basal lamina making these vessels very permeable, allowing the 
passage of red and white  blood cells and serum proteins to pass through with ease 




After exchanging oxygen and nutrients with the tissue and collecting cellular waste, the blood 
is collected into venous system vessels called venules. Venules are very small blood vessels 
which facilitate the drainage of deoxygenated blood from the capillary beds into larger veins. 
The endothelium of venules is discontinuous, so that fluids and solutes can easily re-enter the 
blood stream. Veins generally carry de-oxygenated blood, however like arteries, there are two 
exceptions: the pulmonary and the umbilical vein. The pulmonary vein transports oxygenated 
blood from the lungs back to the left atrium of the heart, where it then flows into the right 
ventricle before being pumped around the body during ventricular contraction. The umbilical 
vein transports oxygenated blood from the placenta to the developing foetus. ECs within veins 
are generally much thinner than within arteries and are shorter and wider due to the lower 
venous flow rates, in comparison to arterial circulation. Veins have looser and more poorly 
organised intercellular junctions than arteries, especially those of post-capillary venules, which 
are the blood vessels that connect the capillary bed to the larger veins [61]. 
As well as venules, the venous system within the human body contains other subtypes of 
veins: deep and superficial. Deep veins are situated within the lower limbs and are normally 
located beside an artery with the same name, for example the femoral artery and vein [69]. 
Superficial veins are located close to the skin and are not paired with an artery. There are two 
main superficial veins within the body; the great saphenous, which transports blood up the 
inner surface of the calf and thigh before joining the deep femoral vein; and the small 
saphenous vein, which occurs on the posterior surface of the calf, and transports blood into 
the popliteal vein [69]. The great saphenous vein is the largest vein within the body and 
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contains between 8 and 20 valves, most of which occur below the knee. Superficial veins are 
located in the subcutaneous fat directly under the skin and are not situated near muscles. This 
results in blood often moving slower within superficial veins than within deep veins, due to the 
lack of nearby muscle for contraction [69].  
Like nearly all vessels within the cardiovascular system, veins consist of three layers; the 
tunica intima, tunica media and tunica externa (Figure 1.3). The tunica intima of venules has 
an absence of elastic fibres, and the tunica media is virtually non-existent (Figure 1.3) [61]. 
The vessel walls of large and small veins contain elastic fibres and smooth muscle cell; 
however compared to arteries their tunica media is not as clearly defined or organised [61]. 
The tunica externa of veins constitutes the majority of the vessel wall, whilst in arteries this 
tunica externa is only about half the overall thickness [61]. In comparison to arteries, veins 
have a much thinner tunica intima, and a thin layer of smooth muscle and elastic fibres in their 
tunica media (Figure 1.3). This is because the vessel walls do not need to be able to withstand 
the high pressure unlike arterial walls. Veins have a much larger lumen than arteries, and 
these features together allow the venous system to accommodate nearly 75% of the blood 
within the body at relatively low pressures, termed high capacitance.  
The blood within veins is not pressurised by the heart and therefore flows at a slower rate 
within the body and requires skeletal muscle contractions to return the blood to the right atrium 
of the heart. This slower moving blood is more liable to pooling and the occurrence of back 
flow, called reflux. To prevent this veins contain bicuspid valves which ensure the one-way 
passage of blood, and are especially important in veins that transport blood back up against 
gravity [70]. In absence or damage of these valves the blood pools, which can disturb the 
exchange of oxygen, nutrients and waste products between the tissues and the blood, which 
can result in chronic venous insufficiency (CVI) [71]. The failure of these valves allows the 
backflow of blood, resulting in venous hypertension due to the failure of reduction of venous 
pressure that normally occurs during exercise, leading to hypoxia and inflammation [71]. 
Chronic venous hypertension causes the endothelium of capillaries within the leg tissues to 
become more permeable, allowing fluid, proteins and blood cells to leak into the tissues [71]. 
The symptoms of CVI include the formation of varicose veins; swollen and enlarged veins that 
occur on the legs, and aching and tiredness in the legs [72].  CVI can occur primary or 
secondary to deep vein thrombosis (DVT). DVT is a serious condition, where blood clots occur, 
commonly within the deep leg veins or the deep veins of the pelvis. This can be caused by 
dysregulation of the ECs lining the blood vessel, causing them to release procoagulation 
factors into the blood, causing the formation of a thrombus. The thrombus can be transported 




After blood is pushed up the vessel, the pressure falls causing the valves to close. The right 
atrium of the heart has a lower pressure than within the veins, providing the driving force for 
venous return [73]. Once reaching the right atrium of the heart, contraction of the heart causes 
the blood to pass through a tricuspid valve into the right ventricle, where it passes through the 
pulmonary artery to the lungs to be re-oxygenated. This oxygenated blood is then transported 
back to the left atrium via the pulmonary vein, where it enters into the left ventricle, to be 
pumped around the body again. 
 
1.2.2 Lymphatic system 
 
The lymphatic system is an open circulatory system composed of structures and vessels that 
drain lymph fluid from tissues and return it to the circulatory system. The lymphatic system 
has three main roles: the removal and filtration of interstitial fluid from tissues, fatty acid 
absorption from the digestive system, and immune function [74–76]. 
Interstitial fluid builds up in tissues due to the hydrostatic and osmotic pressure exerted by 
capillaries from the cardiovascular system forcing fluid into the tissues. The lymphatic system 
drains this excess fluid and large extracellular molecules from the tissues into its own 
lymphatic vessels. The initial vessels of the lymphatic system are blunt-ended capillary vessels 
that are conjoined to the surrounding organs via anchoring filaments [76]. Here, the ECs 
overlap and are joined together by the adhesion protein VE-cadherin in button-like 
arrangement, which act as mini valves allowing fluid to enter the capillaries [76]. When the 
accumulation of interstitial fluid is at a greater pressure than within the lymph vessel, these 
mini valves open, allowing fluid to enter the capillary before closing to prevent lymph backflow. 
In comparison to blood capillaries, lymph vessels are larger and have a greater oncotic 
pressure, which causes fluid to flow into the capillaries after the proteins in the lymph [77].  
As lymph capillaries have no smooth muscle, the increase of pressure during lymph 
accumulation pushes the lymph fluid into larger lymphatic vessels. These larger vessels are 
surrounded by fibrous tissue including collagen, which is used to anchor vessels within the 
body [78]. These larger vessels contain internal valves, like those within veins, and have a 
thin layer of smooth muscle, allowing lymph to be propelled along the vessels and preventing 
backflow [78]. When the pressure of the fluid within the lymph vessel increases to a certain 
point due to increased fluid accumulation, muscular contraction pushes the lymph fluid through 



















Figure 1.5 Valves within lymphatic vessels. Lymph vessels contain valves that 
prevent the backflow of the lymph fluid. Upon pressure, the valves open allowing 
forward transport of the lymph. As the pressure of the vessel decreases, the valves 
close preventing backflow. Adapted from Anatomy and roles of lymphatics in 
inflammatory diseases, Al-Kofahi et al, Clinical and Experimental 





valves in a lymphatic vessel (Figure 1.5) [78]. As the pressure falls, these valves close 
preventing the fluid from flowing back into the vessel [78]. 
Throughout the body the lymph is filtered, removing pathogens and other abnormal solutes.  
This occurs through lymph nodes, which are formed of bundles of lymphoid tissue [79]. 
Unfiltered lymph fluid enters these nodes, which are more densely located around areas 
including the neck, chest and groin, through afferent vessels, and the filtered fluid flows back 
out of these nodes using efferent vessels [80]. The role of these nodes is to filter pathogens 
and other foreign bodies from tissues, where they are presented to lymphocytes to trigger the 
adaptive immune response, and the lymphatic system allows the transport of immune cells 
[75]. 
Fats which have been digested into fatty acids by the digestive system are emulsified and 
converted into lipoproteins called chylomicrons in intestinal cells [74]. The lymph drainage 
vessels that line the intestine absorb these into the lymph fluid, where the chylomicrons then 
enter the blood circulation where they interact with high density lipoproteins before being 
broken down in the liver [74]. 
One of the main principal functions of the lymphatic system is to gather the lymph fluid and 
return it to the blood system for blood homeostasis. If this fluid is not returned to the blood 
system at the same rate it enters the vascular system, the fluid pools and can lead to 
lymphedema [81]. This occurs when there is insufficient lymph drainage, resulting in a build-
up of fluid in the tissues [82]. Lymphedema is a chronic condition, resulting in the dilation of 
the main lymphatic vessels, normally occurring in the legs. This disease cannot be cured, 
however methods, such as compression garments to increase the pressure within the vessel, 
aiding circulation can alleviate symptoms. Lymphatic ECs are affected during lymphedema, 
and excess strain upon the ECs can result in altered collagen deposition, and the release of 
inflammatory cytokines [83]. 
Together, these vessels allow for the efficient transport of fluid within the body, maintaining 
the body in homeostasis. Within these vessels, ECs play an important role in all processes, 
ensuring only the correct solutes enter and leave the vessel and maintaining vessel integrity. 
As these processes described are so crucial for the body to maintain equilibrium, slight 
dysregulation of these can have serious pathological effects, which can affect a range of other 
systems within the body, causing serious clinical diseases including strokes. External factors, 
such as smoking, causes injury to the vessel, and affects the function of the EC within the 





1.3 Endothelial cell subtypes 
 
Despite the endothelium being originally thought of as a homogenous cell layer providing a 
barrier between blood and tissue, more recent studies have discovered that there are multiple 
subsets of ECs, dependent on their location within the vascular system.  ECs can differ 
substantially in their morphology, gene expression and antigen presentation, as well as their 
function. Their properties can differ between organs, between different sections of the organ, 
and even between neighbouring cells within the same organ and blood vessel type [84].  
 
1.3.1 Specific differences between endothelial cells 
 
Typically, ECs are thought of as long, flat cells. However, their thickness can substantially 
differ dependent on their location, from less than 0.1 µM in capillaries and veins, to 1 µM 
thickness in the aorta [85]. There are other differences between ECs; including basal and 
inducible permeability throughout the vascular tree, the expression of coagulation mediators, 
and  the regulation of leukocyte trafficking [84]. 
 
1.3.1.1 Continuous endothelium in the blood-brain-barrier 
 
The blood-brain-barrier (BBB) is a highly specialised structure that separates the blood from 
the brain and cerebrospinal fluid [86]. The properties of the BBB are mainly determined by the 
EC junctions; tight junctions (TJ) and adherens junctions (AJ) [87]. TJs allow the EC to form a 
continuous blood vessel, which is important in ensuring the low permeability of the BBB by 
reducing paracellular diffusion; the diffusion between ECs [88]. AJs are important for the 
maintenance of cell-cell contacts between ECs [89]. This barrier creates a polarised cell with 
distinct luminal and abluminal areas, to prevent the free movement of drugs, and other 
circulating compounds [10].  
ECs in the BBB express ATP-binding cassette efflux transporters, that are required to 
transport lipophilic compounds across the BBB [90]. In other types of ECs, these lipophilic 
molecules can generally pass through the EC membrane, therefore not requiring an efflux 
transporter [90]. Efflux transporters are polarised to the luminal surface of the ECs, and 
transport substances including hormones, phospholipids and cytokines across the plasma 
membrane into the blood using ATP [90]. ABC transporters are expressed by most cells, but 
are most highly expressed in barriers, including the BBB, and excretory and absorbing tissues, 
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such as the liver and intestine [90].  ABCB1 is a transporter protein that is highly expressed 
upon the apical surface of the BBB, and has a wide substrate specificity, allowing the 
transporter to be an effective defence against a wide range of xenobiotics and therapeutic 
drugs [91]. The ABCB1 transporter is thought to be the most important ABC transporter in 
neuroprotection, as it limits the entry of exogenous molecules into the brain [91]. Reduced 
expression of ABCB1 is associated with neuropathologies including Alzheimer’s disease, 
where the expression of ABCB1 was shown to be significantly inversely correlation with the 
deposition of β-amyloid plaques by Vogelgesang et al (2002) [92]. Other types of ABC 
transporters include the ABCC family, which are efflux transporters involved in multi-drug 
resistance, and show preference for anionic substrates [90]. Evidence has shown that 
oxidative stress and xenobiotics increase the expression of these transporters at the BBB [90].  
 
1.3.1.2 Discontinuous endothelium in the liver  
 
The liver is an organ within the human body that is involved in multiple processes, including 
digestion, detoxification, and immunity. The liver is involved with processing nutrients 
absorbed from the small intestine. Liver cells, also called hepatocytes secrete bile, a fluid 
composed of water, bile salts, cholesterol and other substances, that are involved in the 
digestion of lipids in the duodenum. The liver is also able to convert potentially toxic lipophiles 
into more water-soluble metabolites, that can be excreted from the body via urine [93]. As the 
liver is exposed to bacteria from the gut, and toxins within the body, the liver contains 
specialised Kupffer cells; specialised macrophages that line the walls of sinusoids, 
discontinuous capillary vessels [94]. 
As previously mentioned, discontinuous capillaries have open spaces between ECs and a 
discontinuous or absent basement membrane (Figure 1.4). These sinusoids act as a selective 
barrier between the blood, which contains molecules containing nutrients and bile acids on 
ECs luminal side, and hepatocytes involved in metabolism on their abluminal side [95]. Liver 
sinusoidal ECs (LSECs) are the most permeable ECs within the human body, due to their 
fenestrae, absence of a diaphragm and lack of an underlying basement membrane [95]. 
Metabolites, plasma proteins and drugs, amongst other solutes present within the vessel are 
able to pass through these gaps to be transported into the hepatocytes surrounding the 
capillary. LSECs have one of the highest endocytic capacities, and strong lysosomal activity, 
allowing LSECs to clear pathogens and macromolecules from the blood [95]. LSECs are able 
to rapidly endocytose these compounds from the blood through scavenger and mannose 
receptors, working alongside Kupffer cells which clear larger particles by phagocytosis [96]. 
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During liver cirrhosis, the scarring of the liver caused by long-term damage which can be 
causes by excess alcohol consumption or hepatitis, LSECs lose their fenestrae and a 
basement membrane forms [97]. This reduces the permeability of these cells, which can cause 
serious health problems including jaundice, and can be fatal [97]. 
 
1.3.1.3 Fenestration endothelium in the kidney 
 
The kidneys are excretory organs that remove toxins from the body by filtering the blood, 
resulting in the production of urine. The kidneys are also involved in other processes, such as 
regulating the body’s water balance controlling blood pressure, ensuring the blood is not too 
acidic or alkaline, and produce the hormone EPO, which promotes the formation of red blood 
cells by the bone marrow [98]. The filtration of blood occurs within the glomerulus, a network 
of blood capillaries that are located at the beginning of nephron, the functional unit of a kidney. 
Unusually for capillaries, the glomerular capillary wall consists of three layers; highly 
fenestrated endothelium; glomerular basement membrane (GBM); and the foot processes of 
glomerular epithelial cells which wrap around capillaries leaving slits between them, as well 
as providing support to the vessel [99]. The endothelium that makes up the capillaries of the 
glomerulus is extremely fenestrated, with pores covering 30% to 50% of its surface area which 
are covered by diaphragms (Figure 1.4) [100]. In comparison to other ECs, ECs within the 
glomerular filtration barrier are also extremely flat, and the luminal surface of the glomerular 
ECs is covered by a glycocalyx with a high heparan sulphate content [99,101].These 
adaptions allow for the high permeability of the capillary to water and small solutes through 
the 60- to 80-nm fenestrae, whilst preventing the passage of cells and large proteins such as 
albumin through the capillary wall as they cannot fit through the pores [100]. Vascular 
endothelial growth factor (VEGF) plays a role in the formation of EC fenestrations [102]. 
Patients with type 2 diabetes mellitus; a metabolic disease that causes high blood sugar levels 
due to the insensitivity to insulin, can develop diabetic nephropathy. This cause the 
overproduction of reactive oxygen species that can damage the glomerulus, and upregulated 
production of the enzyme heparanase, which degrades the glycocalyx of the glomerular ECs 
[103]. The GBM also thickens, and the podocyte foot processes detach from the GBM, 
increasing the permeability of the glomerular filtration barrier [101]. This results in the passage 
of large proteins including albumin to pass through the capillary walls, and be present within 
the urine, an early indicator of kidney damage [103].  If this disease becomes advanced, and 
the kidneys are unbale to effectively filter the blood, treatment can include kidney dialysis, 
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where the blood passes along a tube into an external machine for filtration to effectively 
remove toxins from the blood.  
 
1.3.2 Mechanisms of endothelial cell heterogeneity 
 
ECs require different properties, dependent on their location within the vascular tree. Until the 
late 1990s, the differences between ECs was thought to be dependent on the exposure of 
cells to flowing blood. However, more recent investigations have shown that EC heterogeneity 
is not only due to their environment, but also has a genetic component that may play a role 
before the differentiation of angioblasts into ECs [102].  
During the early stages of embryogenesis during the development of blood vessels, signalling 
molecules are thought to be important in the initial decision of whether the ECs should be 
arterial or venous. During development, high levels of VEGF induce arterial specification by 
activating phospholipase C (PLC), which activates the mitogen-activated protein kinase (MEK) 
and extracellular signal regulated protein kinase pathways (ERK) [102]. These pathways 
activate subsequent signalling molecules, including upregulation of Notch and Nrp-1 to 
proceed arterial specification [102]. When the ERK pathway is supressed due to low levels of 
VEGF, and the protein kinase B (AKT) pathway induces COUP-TFII, a protein that 
downregulated the Notch and Nrp-1, causing the expression of venous-specific markers [102]. 
A subgroup of these venous ECs  are specified into becoming lymphatic ECs, by expressing 
Sox18 and Prox1 [102]. Where Notch signalling is deficient, Hill-Felberg et al (2015) found 
that zebrafish lose their expression of Eph B2, a ligand that is the marker for arteries, but 
instead ectopically expresses Eph B4, which is normally associated with veins [104]. When 
Notch signalling is either reduced or constitutively active, arteriovenous malformations (AVM) 
can develop [104]. These AVMs can be asymptomatic, but if the AVM occurs in the brain, 
symptoms such as epileptic seizures and headaches can occur [104]. 
Despite this early molecular specificity of the ECs final identify, ECs have plasticity for further 
differentiation dependent on their location within the body. For example, variable blood flow in 
the aorta results in a non-uniform distribution of atherosclerotic plaques [105]. Laminar blood 
flow in the aorta induces the expression of eNOS and thrombomodulin, conferring an anti-
thrombotic and anti-inflammatory properties to the endothelium [105]. Non laminar flow, such 
as at areas where the arteries branch reduces the expression of eNOS, but induces the 




However, as well as properties of the ECs being controlled by their microenvironment, ECs 
are also able to be controlled via epigenetics: heritable changes in gene expression that do 
not alter the DNA sequence [85]. Epigenetic modifications are semi-conserved during mitosis 
and meiosis, but can also occur in response to signals from the surrounding environment, or 
in response to pharmacological intervention [106]. There are two types of epigenetic 
modification: DNA methylation, and histone modification, which can positively or negatively 
influence gene expression [84]. By analysing gene expression and methylation patterns of 
vascular ECs and lymphatic ECs, a significant set of genes were identified with different 
methylation patterns and gene expression [107]. For example, the lymphatic specific gene 
promoter IL-7 is differentially methylated between these lymphatic and vascular endothelial 
subtypes. IL-7 is upregulated in lymphatic ECs where the gene is hypomethylated, compared 




















1.4 Secretory Pathway 
 
1.4.1 Epithelial secretion  
 
The term ‘epithelial cell’ encompasses cells which line both the internal and external surfaces 
of the body, therefore ECs are a subset of epithelial cells [108]. The majority of epithelial cells, 
including ECs have a defined apical and basal membranes, which differ in their structure, 
composition and function, for example ciliated epithelium in the respiratory tract only has cilia 
on the apical surface of the cell [108,109]. Epithelial cells interact with the extracellular matrix 
(ECM) via integrins, transmembrane proteins which anchor cells to the ECM (Figure 1.1) [108]. 
The molecular mechanisms that determine apicobasal polarity in ECs are unclear, however, 
important insights may come from the extensive studied polarisation of epithelial cells [110]. 
Cellular polarisation underlies processes including cell-cell signalling, cellular division, and cell 
migration, and is therefore important for almost every cell type [111]. The polarisation of 
epithelial cells is maintained by protein complexes which are localised at the apical membrane 
and is essential in maintaining apicobasal polarity [112]. There are three main protein 
complexes involved in regulating epithelial cell polarity, Crumbs, Par, and Scribble [113]. The 
Crumbs and Par complexes are located apically, and the Scribble complex is basolaterally 
located [113]. The composition, cellular location and function of these complexes is 
evolutionary conserved [112]. Whilst is it is not exactly known how these complexes define 
the polarity, the antagonism between these complexes excludes Crumbs and Par from 
entering the basolateral domain, and Scribble from entering the apical domain [113,114]. This 
antagonism occurs by methods including phosphorylation of components of the Scribble 
complex, preventing its accumulation at the apical surface [111]. This establishment of polarity 
allows the segregation of certain organelles such as the nucleus to the basal side and cellular 
extensions such as cilia present on the apical surface. Tight junctions separate the apical and 
basolateral compartments of epithelia by prevent the lateral diffusion of intramembrane 
components [115].  
The apical and basolateral plasma membrane domains differ in their protein and lipid 
composition, with certain transporters, ion channels and enzymes are specifically enriched in 
apical or basolateral membranes [116]. The apical membrane of epithelial cells is enriched 
with glycolipids and cholesterol, whilst the basolateral membrane contains many cell adhesion 
proteins  [117]. The lipids and proteins need to be sorted to the correct target location to 
maintain polarity. 
There are three main types of epithelial cell: squamous, cuboidal and columnar, which can be 
only one cell layer thick (simple), or two or more layers thick (stratified). Squamous epithelial 
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cells appear as flattened cells, with an almost oval shapes nucleus. ECs are a type of 
specialised squamous epithelium tissue, as are mesothelial cells, which line the body’s 
cavities [118]. Mesothelial cells secrete a non-adhesive protective surface for the body’s 
internal surfaces and unlike ECs, can consist of several cell layers [119]. Cuboidal ECs have 
a large spherical nucleus which is central within the cell. This type of epithelium is found in the 
ducts of glands and is actively involved in the secretion and absorptions of molecules. In 
smaller glands, this epithelial tissue is often squamous, with stratified epithelial tissue in larger 
glands such as salivary glands [120]. Columnar epithelial cells are rectangular shaped cells, 
with their nucleus located toward the basal side of the cell and contain lots of Golgi and 
endoplasmic reticulum [118]. Columnar epithelial cells are commonly found within the 
digestive tract where the cells express features upon their apical surface such as microvilli, to 
increase the surface area for absorption, or cilia to waft mucus, which has been secreted by 
a type of modified epithelial cells called goblet cells [118].  
The apical surface of epithelial cells is often covered in microvilli and contains most of the 
proteins required for functions such as digestion, and nutrient absorption [114]. The apical 
membrane is also generally enriched in sphingomyelin-containing glycolipids, and glycolipid-
anchored proteins [114]. The basolateral cell surface is enriched in plasma membrane proteins 
such as transferrin and low-density lipoprotein receptors, and Na+K+ATPase, which are 
required for fundamental cellular processes [121]. One of the major roles of epithelial cells is 
secretion. In the intestine epithelial cells need to secrete molecules into the gut, such as 
digestive enzymes to break down food, and mucus into the lumen to lubricate the gut lining to 
aid the passage of material along the gut. These molecules are secreted from the apical 
surface of the epithelial cells, whilst endocrine epithelial cells in the gut secrete hormones from 
their basolateral surface. 
One of the major roles of epithelial cells is polarised secretion of proteins. The destination of 
these proteins is known by the addition of sorting signals, which are recognised by specific 
cellular sorting machinery at the TGN and in recycling endosomes before incorporation into 
apical and basolateral sorting vesicles [122]. Apical sorting signals include N- and O- linked 
glycans, and glycophosphatidylinositol (GPI)- anchors which are attached to the protein [117]. 
During the translocation and elongation processes of the polypeptide chain during protein 
synthesis by ribosomes, N-linked glycans are attached to an asparagine residue within an N-
X-T/S consensus sequence within the polypeptide chains [123]. There is not currently an O-
linked glycosylation consensus sequence.  After the N-linked glycans have been correctly 
modified by glucosidases and α-mannosidases, and the polypeptide chain has been correctly 
folded in the endoplasmic reticulum (ER), the protein is exported to the Golgi. Within the Golgi, 
the plasma membrane proteins are further glycosylated, before being trafficked to the apical 
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cell surface. The mechanism by which N-linked glycans are apically sorted is weakly 
understood. The mannose-binding lectin VIP36 and the galactose-binding lectin, galectin-3 
are potential sorting receptors for N-linked glycans [123]. VIP36 is predominantly expressed 
in the cis-Golgi and the ER-Golgi intermediate compartment (ERGIC), and has been found to 
promote sorting of several apical glycoproteins [124]. Over expression of VIP36 in MDCK cells 
increased the apical content of VIP36 and VIP36-recongised glycans [124]. Galectin-3 has 
been shown to directly interact with certain apical glycans, and depletion of galectin-3 in MDCK 
cells results in the mis-sorting of these apical glycans to the basolateral membrane [125]. 
Galectin-3 is also suggested to be able to sort O-linked glycans [123].  
The abundance of several proteins within the apical membrane has been shown to decrease 
when N-glycans are removed. For example, when some of the 7 N-glycosylation sites of the 
gastric H-K-ATPase β-subunit in LLC-PK1 were mutated, the distribution of the protein 
changed [126]. Normally, the correctly glycosylated β-subunit is 40% detected in the ER, and 
60% amongst the plasma membrane, Golgi, and endosomes [126]. Removal of the N1, N3 
and N5 increases the amount of protein retained in the ER, and removal of N7 leads to virtually 
total retention in the ER [126]. The O- linked glycan sorting signal works in a similar 
mechanism [125]. 
Basolateral sorting does not involve the addition of glycans but involves the recognition of 
signal sequences. The most common sorting signals for basolateral proteins include tyrosine 
peptide motifs, which has the consensus sequence NPXY or YXXØ, or dileucine motifs which 
have the consensus sequence D/EXXXLL within their cytoplasmic domain [127].  
At the TGN, proteins are sorted into membrane bound vesicles destined for their required 
location. Lipid rafts have been suggested to be sorting platforms within the TGN for delivery 
of proteins to the apical membrane [128]. Lipid rafts are subdomains of the plasma membrane 
that contain higher levels of cholesterol and glycosphingolipids than other areas of the PM, 
increasing their stability. GPI anchored proteins oligomerise into lipid rafts, however, it is 
uncertain whether GPI-anchoring alone is sufficient to specify proteins to the apical 
membrane, and may require N-linked glycans [127]. However, apical trafficking using N- and 
O- glycans can also be lipid raft independent [128]. Another type of transporting apical proteins 
is by first transporting them to the basolateral surface, where they then undergo transcytosis 
to the apical surface [129]. This indirect pathway is commonly used within hepatocytes [129]. 
The basolateral sorting motifs are very similar to those that interacts with clathrin-adaptor 
complexes in endocytosis and lysosomal sorting, giving rise to suggestions that clathrin may 
be involved in basolateral sorting  [129]. For some proteins targeted to the basolateral surface, 
such as transferrin receptors, have shown to be indirectly transported via endosomes [129]. If 
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these basolateral sorting signals are removed, basolateral proteins are generally transported 
to the apical surface, and if the sorting sequences were moved to the cytoplasmic domains of 
apical proteins, the proteins were transported to the basolateral surface [121].  
The membrane of secretory vesicle are enriched in proteins such as Rab11a, Rab8a, and 
Rab27, which are able to recruit v-SNAREs, for example Slp4a [116]. Slp4a binds to the t-
SNARE syntaxin-3 on the plasma membrane, along with the Sm protein Munc18-2 to allow 
fusion to the plasma membrane [116]. Another v-SNARE protein present within the secretory 
vesicle membrane is Vamp7, which is also able to interact with syntaxin-3 on the plasma 
membrane [116]. This docking brings the vesicle into close proximity, where it can fuse and 
secrete its contents outside of the cell. Exocytosis can be either constitutive, where secretion 
occurs continuously, or regulated, for example regulation via Ca2+ concentration [130].  
An example of where polarised secretion is important is within the small intestine. Here, the 
polarisation of epithelial cells allows the epithelial intestinal cells to be specialised for 
absorption of nutrients, whilst providing a barrier against pathogens. The small intestinal 
epithelial cells form villi and crypts, increasing the surface area of the small intestine. The 
intestine contains multiple different types of simple columnar epithelial cells; including the 
secretory goblet cells, Paneth cells, and enteroendocrine cells; as well as absorptive 
enterocytes, and tuft cells [131]. The villi are formed of enterocytes, which have microvilli upon 
their apical plasma membrane to maximise surface area, and goblet cells secrete mucus to 
protect the intestine wall from acids and gases produced by gut bacteria. The base of the 
intestinal crypts contain Paneth cells, which secrete antimicrobial peptides including alpha-
defensins into the crypt lumen via merocrine secretion [132]. Paneth cells are specialised 
secretory cells, with their nucleus towards the basal side of the cell, containing extensive ER 
and Golgi, and accumulate secretory granules towards the apical surface of the cell [132]. The 
intestinal crypts also contain stem cells and goblet cells. Many of the digestive enzymes 
present within the small intestine are produced by the pancreas. The pancreas contains 
exocrine acinar cells, which are highly polarised with their apical pole densely packed with 
digestive enzymes, including trypsin, lipase and amylase to secrete via exocytosis [133]. 
These enzymes enter the small intestine via the pancreatic duct, which is lined by ductal cells 
[134].  
The small intestine is also an endocrine organ, meaning it can secrete hormones directly into 
the blood and tissue. Finger like apical projections expressed by enteroendocrine cells 
(EECs), can detect specific nutrients present in the intestinal lumen. This detection causes the 
secretion of peptide hormones contained in secretory granules from the basal surface, which 
can then activate receptors on proximal cells, enter the blood, or stimulate receptors on 
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neurons [135]. These secreted hormones include cholecystokinin (CCK), which is secreted by 
enteroendocrine cells within the intestine in response to a meal, and causes the release of 
digestive enzymes from the pancreas, as well as mediating satiety, and histamine which 
increases acid secretion [135]. 
Disruption in the polarity of epithelial cells can have a significant effect upon the organisms. If 
the apical proteins are disrupted, malnutrition occurs due to inability to absorb nutrients across 
the apical membrane, and mislocalisation of the basolateral proteins is associated with cancer 
development and inflammatory bowel disease [131].  
 
1.4.2 Extracellular vesicles 
 
Intracellular communication is an essential function of multicellular organisms. Cells 
communicate in numerous different ways, including cell-cell contact, intracellular transfer of 
secreted molecules and intracellular transfer of extracellular vesicles (EVs). EVs are an 
important mechanism of intracellular communication and are released by cells under both 
physiological and pathological conditions, and dock at the membrane of a target cell causing 
a response [136]. These EVs have a variety of functions, including the transport of DNA, RNA, 
and miRNA [137]. Two types of EVs are exosomes and microvesicles (MVs) (Figure 1.6). ECs 
are able to release both exosomes and MVs [136]. One major challenge in the study of 
exosomes and MVs is the difficulty discriminating between these two types of EVs, as size 




Exosomes are 40-100 nm extracellular lipid vesicles, which are released as a consequence 
of multivesicular endosome fusion with the plasma membrane (Figure 1.6) [138]. Intraluminal 
vesicles (ILVs) are formed by invagination of the endosomal membrane, and endosomes 
accumulate ILVs within their lumen, forming multivesicular bodies (MVBs) (Figure 1.6) [138]. 
Not all MVBs containing ILVs become exosomes, and other fates include fusion with 
lysosomes, the generation of specialised organelles such as wPB, or fusion with the plasma 
membrane [138]. Whilst it is currently unknown how the fate is decided, the cholesterol levels 
of the MVB membrane appear to play a role, with cholesterol-poor MVBs fusing with 













Figure 1.6. Release of microvesicles and exosomes. Microvesicles are released 
directly by budding off from the plasma membrane. The release of exosomes occurs by 
interluminal vesicles fusing with EEs, before being released by the fusion of MVBs with 
the plasma membrane. Other MVBs fuse with lysosomes. Adapted from Extracellular 
vesicles: Exosomes, microvesicles and friends, Raposo and Stoorvogel, Journal of Cell 
Biology; published by Rockefeller University (2013) [136]. 
CCV: Clathrin coated vesicle, EE: Early endosome, MVB: Multivesicular body  
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with the plasma membrane of the  cell, the contents is released to the external environment  
as exosomes (Figure 1.6) [138].  
Exosomes were initially thought to be involved in removing cellular waste, but recently it has 
been found that exosomes capable of carrying proteins, lipids and DNA amongst other 
substances [138]. Exosomes are released from nearly all eukaryotic cells, and are thought to 
be involved in many cellular processes, including immune response and cell-cell 
communication [139].  
The study of exosomes is a recent advancement and there has been increasing interest on 
their biological significance, and the implications of exosomes in disease states [140]. One 
study by Davidson et al (2018) investigated whether exosomes released by ECs could be 
cardioprotective [141]. In hypoxic conditions, co-culture with HUVEC and cardiomyocytes 
decreased cell death when compared to cardiomyocytes culture alone, suggesting that 
HUVEC can release cardioprotective factors, which they later confirmed as exosomes by 
transmission electron microscopy and flow cytometry [141]. This study, as well as other 
studies using different cell types suggest that exosomes could be used as therapies [142].  
When there is a high level of blood sugar within the body, which can occur during diabetes 
mellitus, ECs can become activated meaning they express proinflammatory and procoagulant 
proteins upon their surface. In one study by Sáez et al (2019) exosomes were found to be 
able carry molecules involved in EC activation such as the cellular adhesion ICAM-1 [143]. 
This study showed that exosomes may deliver ICAM-1 to monocytes, and exosomes may 
increase the expression of these adhesion molecules, inducing and maintaining the activation 
of both cell types during hyperglycaemia [143]. Exosomes have also been proposed as useful 




Microvesicles (MVs) are another type of extracellular vesicle released from the cell membrane 
that are involved in cell-cell communication, and are approximately  0.1 – 1 µm in diameter 
(Figure 1.6) [136]. Unlike exosomes, which are formed in MVBs, MVs occur by direct budding 
from the plasma membrane (Figure 1.6) [136].  
Like exosomes, MVs are capable of transporting molecules including mRNA and proteins. The 
content of microvesicles depends on the microenvironment and the triggers preceding the 
release of the microvesicles. The shedding of MVs occurs from micro-domains within the 
plasma membrane called lipid-rafts, regions of the plasma membrane which contain high 
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concentrations of cholesterol [145]. Many cells are capable of releasing MVs from their plasma 
membrane, including ECs. MVs are released under physiological conditions in ECs, such as 
cell growth. The amount of microvesicles released by ECs increases during EC activation, 
which occurs due to conditions such as cell injury, hypoxia and shear stress [145]. Dependent 
on the condition that MVs are released, such as between shedding and apoptosis, MVs have 
express a different repertoire of surface receptors and cytoplasmic components [145] 
Endothelial MV can be indicators of diagnosis and prognosis of health conditions [140]. The 
process of MV release is thought to be highly regulated and occurs in many cell types, with 
MVs being detected in blood and other bodily fluids [146].  
However, like exosomes, the exact mechanism of formation and secretion of MVs is unknown, 
however the release of MVs shows similarities to that of viral budding [146].  
 
1.4.3 Endothelial cell secretion 
 
As previously discussed, the ECs act as a dynamic organ, interacting with both the circulating 
fluid and the underlying tissue. Whilst most of the mechanisms are similar to other cell types, 
ECs have unique features, due to their roles within processes such as blood haemostasis 
[147].  
Von Willebrand factor (vWF) is synthesised within ECs and is either secreted directly, mainly 
as low molecular weight VWF through the constitutive pathway, or stored within Weibel-Palade 
bodies (WPB) (Figure 1.7) [148]. Within ECs, vWF is initially formed as a monomer within the 
ER consisting of a signal sequence, pro-peptide and the mature protein, before being 
dimerised using disulphide bonds [147]. The dimerised vWF is transported to the Golgi; an 
organelle associated with the modification and transport of proteins, where O- glycosylation 
occur, and vWF becomes a multimer [147]. These vWF multimers then have two fates; either 
to be constitutively secreted by the EC or stored with WPBs. 
WPBs are endothelium specific organelles and contain chemokines such as IL-8 and 
endothelin-1, as well as vWF. The formation of the WPBs starts at the TGN, and is dependent 
on the adaptor protein AP-1 and clathrin [147]. During maturation, WPBs recruit other 
components including Rab GTPases (Rab27A, Rab3B/D, and Rab15) and Rab effectors 
(MyRIP, Slp4-a and Munc13-4), which allow the WPB to become ready for secretion [149]. 
SNARE complex proteins, molecular machines that are involved in the exocytosis of secretory 
vesicles, interact with these proteins [149]. The assembly of these SNARE proteins brings the 








Basal release Regulated 
release 
Figure 1.7. Release of vWF from endothelial cells. Von Willebrand factor (vWF) is 
constitutively released from endothelial cells solely from the basolateral surface. Under 
basal and regulated release, secretion of vWF occurs predominantly apically, with little vWF 
secreted via these methods from the basolateral surface. The secretion of vWF via the 
basal and regulated secretion occurs from Weibel-Palade bodies. The length of the arrow 
correlates the relative secretion of vWF. Adapted from Von Willebrand Factor 
multimerization and the polarity of secretory pathways in endothelial cells, Lopes da Silva 




secreted as high molecular weight vWF when the EC is activated, but also under basal 
conditions [148].  
The largest amount of regulated VWF is secreted as long strings of vWF polymers apically 
into the blood vessel lumen where it can recruit circulating platelets; an important stage in 
coagulation [150]. However, constitutive release of vWF is exclusively targeted to the 
basolateral surface (Figure 1.7). AP-1 is involved in the delivery to the basolateral surface, 
however, how AP-1 is involved in this targeting is uncertain [150].  
In steady state most ECs are quiescent, meaning they are not actively dividing, and favour 
tumour dormancy. However, ECs are able to be rapidly activate in response to physiological 
stresses such as hypoxia, inflammation, and the upregulation of angiogenic factors. These 
stresses can cause the ECs to secrete specific molecules. Other important molecules secreted 
by ECs include matrix metalloproteinases (MMPs). One specific MMP, MMP-14, has shown 
to be of vital importance during development in lung ECs. MMP-14 is required for 
alveolarization, and MMP-14 KO mice have decreased alveolar surface area which results in 
decreased lung function [151]. The secretion of ECs can also change in response to injury 
and play an important role in repair of the vessel. ECs in the lung capillary secrete MMP-14 
after surgical removal of part the lungs, which allows activation of EGF-like ligands, promoting 
repair to the lungs by stimulating the proliferation of epithelial progenitor cells [152]. Liver 
sinusoidal ECs (LSECs) are also involved in tissue regeneration. After a partial hepatectomy 
LSECs established a vascular niche that releases angiocrine growth factors, such as the bone 
morphogenic proteins BMP2 and 4, involved in organ regeneration [153].  
Other stresses, including shear stress are able to induce secretion of other factors from ECs. 
Shear stress refers to the force of the flowing blood on the EC surface stimulate EC cell 
signalling pathways such as the MAPK and PI3K transduction pathways, resulting in the 
secretion of subset of molecules, including platelet derived growth factor (PDGF) [154]. PDGF 
is a powerful mitogen for vascular smooth muscle cells causing them to switch from a 
contractile to proliferative state, so is involved in the regulation of cell growth and proliferation, 
especially within angiogenesis [155]. Whilst the secretion of these molecules can have 
practical results, such as repair of tissue, they can also be implicated in pathogenic 
complications. For example, PDGF is a potent chemoattractant for smooth muscle cells, which 
is a critical event in atherosclerosis [154]. PDGF causes migration of smooth muscle cells into 
the tunica intima of arteries, which form part of the fibrous cap of the atherosclerotic plaque 
[65]. This invasion of smooth muscle cells into the arterial tunica is also aided by the secretion 
of proteolytic MMPs from ECs, especially MMP-9. Under basal conditions MMP-9 is not 
produced by ECs, but is induced by cytokine activation of ECs [156]. MMPs are involved in 
37 
 
the degradation of the extracellular matrix, allowing smooth muscle cells to enter the tunica 
intima [66]. 
ECs are also able to synthesise and secrete vasoactive substances, including the vasodilators 
NO and prostaglandins, hyperpolarisation factors, and vasoconstrictors angiotensin and 
endothelin 1 (ET-1) [157]. Under normal conditions ET-1 is produced in small amounts, 
regulating blood pressure and reducing the heart rate, however in pathological conditions the 
production is increased [158]. The secretion of ET-1 is stimulated by factors such as thrombin, 
hypoxia and adrenaline, and may decrease eNOS expression reducing NO production [159]. 
ET-1 is involved in endothelial dysfunction, as ET-1, the ET receptors and the biological effects 
controlled by ET-1 become more pronounced during cardiovascular disease [158]. 
The substances secreted by ECs are of considerable importance. However, these factors 
need to be secreted from the correct surface of the ECs, to ensure they can perform their 
required function. 
 
1.4.4 Polarised EC secretion 
 
ECs can secrete different proteins from the apical and basolateral surface of the cell, such as 
the secretion of IL-8 from the apical, and MIC-1 from the basolateral surface [160]. Whilst there 
have been vast studies into the polarised secretion of epithelial cells, there are few studies 
into the polarised secretion of ECs and the sorting mechanisms used [33,114,123,160,161]. 
Some studies have suggested that the mechanism used within epithelial cells are not the same 
as used within endothelial cells, highlighting the need for further investigations into this area. 
One protein which has been shown to be involved in the HUVEC polarised secretion is liprin-
α1. Liprin-α1 is involved in a method of trafficking vesicles from the Golgi to the basolateral 
membrane in a Rab11B-dependent pathway, which uses microtubules for vesicle 
transportation. Cells are anchored by to the ECM via large macromolecular assemblies on the 
basolateral membrane called focal adhesions (FAs), which transmit mechanical force and 
regulatory signals between the ECM and the cell. The assemblies contain integrins, which 
anchor the cell to the ECM via their extracellular region, and their cytoplasmic tale is connected 
to the actin cytoskeleton.  
One of the protein complexes involved in anchoring microtubules to the FAs is the cortical 
microtubule stabilising complex (CSMC) [1]. The CSMC interacts with plus-end trafficking 
proteins of microtubules such as KIF21A, and associate with FAs proteins such as talin [1]. 
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One of the proteins involved in the CSMC is liprin-α1, which interacts with the protein tyrosine 
phosphate receptor type f polypeptide (PTPRF) and localises it to the FAs [2]. 
Liprin-a1 is a member of the leukocyte common antigen related (LAR)-interacting family, 
alongside other liprin-α and liprin-β cytosolic adaptor and scaffold proteins [3]. The liprin-α 
proteins have mainly been previously studied in neurons, where they are involved in synapse 
functions [3]. In non-neuronal cells, including ECs, liprin-α1 proteins have been shown to have 
roles within cell adhesion, cytoskeleton organisation and signal transduction, as well as FA 
dynamics [3]. 
A study by Mana et al (2016) showed that liprin-a1 was involved in the trafficking of FN to the 
basolateral surface of ECs [2]. Within the cell, FN dimers are proposed to associate with the 
α5β1 integrin in vesicles and be transported to the basolateral plasma membrane in a Rab21 
dependent pathway. Mana et al (2016) showed when liprin-α1 was depleted, the secretion of 
FN from the basolateral surface was depleted. 
In order to maintain the non-thrombogenic surface of ECs, ECs polarise secretion of basement 
membrane components to the basolateral surface of ECs, including fibronectin (FN). In newly 
confluent cultures, Kowalczyk et al (1990) found that FN was secreted equally from both the 
apical and basolateral surface of ECs of pre confluent and newly confluent cultures, whilst in 
post-confluent cultures FN was predominantly secreted from the basolateral surface [33]. This 
study showed that ECs also have binding sites for FN upon their confluent basolateral surface, 
where polymerisation can occur [33]. This suggests one possible method of ensuring FN 
polymerisation only occurs upon the basolateral surface of ECs [33]. 
In epithelial cells, N-glycans normally direct proteins to the apical membrane, however a study 
by Jurczyluk et al (2003), found no evidence for this sorting mechanism in ECs [160]. IL-8 and 
GM-CSF were predominantly secreted from the apical surface, and MIC-1 from the basolateral 
surface. However, the study found that the N-glycosylated proteins IL-8 and pro-MIC-1 were 
sorted to both the apical and basolateral surfaces of HUVEC, suggesting sorting may not be 
related to glycosylation within ECs [160].  
Other cytokines show polarised secretion in ECs. A study by Verma et al (2006) found that IL-
6, GM-CSF and TNF-α were secreted from the apical and basolateral surface of ECs, whilst 
IL-1α and IL-10 were found to be solely secreted from the apical surface from microvascular 
brain endothelial cells (MBEC) [161]. This study also found that stimulation by 
lipopolysaccharide  to either surface of the EC can stimulate polarised cytokine release, 
supporting the results that MBEC release  [161]. 
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As vasoactive substances act upon the smooth muscle cells underlying the ECs, it would imply 
that these substances were released form the basolateral surface of ECs. The vasoactive 
substance endothelin-1 released from ECs has been shown to be predominantly secreted 
from the basolateral surface of cultured HUVEC, with 80% of the total amount being found in 
the basal media [162]. 
This polarisation ensures the secretion of substances to the desired location. If molecules are 
not accurately sorted and secreted from the correct surface of the EC, there can be significant 

























There are a number of drugs that have been shown to affect ECs, including angiotensin-
converting enzyme (ACE) inhibitors which are used to treat hypertension, and beta blockers, 
which reduce the heart rate [163]. Another drug thought to affect ECs are statins, which are 
suggested to have an anti-inflammatory effect. Statins are predominantly used for reducing 
high blood cholesterol levels, which is one of the most important risk factors in the 
development of coronary heart disease [164]. However, they may also have additional roles 
that are not yet appreciated [164]. 
Statins affect the cholesterol synthesis pathway, by competitively inhibiting 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase, which converts HMG-CoA to mevalonate. 
This inhibition results in increased expression of cell surface LDL receptors, therefore 
increasing cellular uptake of LDL and reducing circulating cholesterol. 
The formation of an atherosclerotic plaque is a complex multifactorial process, involving the 
build-up of cholesterol, inflammation, and EC dysfunction. The inhibition of HMG-CoA 
reductase also inhibits other downstream products of the mevalonate pathway, including the 
synthesis of isoprenoid intermediates such as farnesylpyrophosphate (FPP) and 
geranylgeranylpyrophosphate (GGPP) [165]. These intermediates serve as lipid attachments 
for various intracellular signalling molecules, including the small GTP-binding proteins Rho, 
Rac and CDC42 [165]. The inhibition of these proteins is thought to play an important role in 
the positive biological effect of statins on endothelial cells. 
The inhibition of Rho and Rac prenylation by statins has been shown to improve EC 
dysfunction, by increasing the production of NO by increasing the expression of eNOS [166]. 
This promotes vasodilation, which can be impaired by other known risk factors for 










1.6 Aims of Project 
 
The aims of my project are to analyse the normal HUVEC polarised secretome, and to 
investigate the changes that occur in different conditions. I will be comparing the normal 
HUVEC polarised secretome to the polarised secretome where liprin-α1 is silenced and 
examining which proteins secretion is changed. As there is currently very limited information 
about the mechanisms EC use for secretion, this investigation will allow me to suggest which 
proteins involve liprin-α1 in their secretion. This information will allow further investigations to 
be performed to aid elucidation of the mechanisms of EC secretion. 
I will also be comparing how atorvastatin addition affects the polarised secretome of HUVECs. 
Atorvastatin is one of the most commonly prescribed drugs for reducing cholesterol, which 
acts by inhibiting the HMG-CoA reductase pathway. In my study, I aim to investigate whether 
atorvastatin changes the polarised secretome of HUVEC, and whether atorvastatin has any, 
previously unknown pleiotropic effects. These effects could possibly highlight other disease 
conditions that atorvastatin may have therapeutic potential for. This study could also highlight 
counterindications where atorvastatin should not be given as treatment. As statins are such 
an important drug within the UK health system, my study will provide valuable information 




Chapter 2 Materials and Methods 
2.1 Reagents 
 
2.1.1 Cell Culture   
 
Mammalian cell line Source 
HUVEC Human umbilical vein endothelial cells, 
Lonza, CC-2519, pooled donors 
 
Cell culture media type Components 
EBM-2 Endothelial cell basal medium-2, Lonza, 
CC-3156 
Endothelial cell growth medium (EGM-2) Endothelial cell basal medium (EBM-2) 
supplemented with BulletKit minus vascular 
endothelial growth factor, Lonza, CC-4176 
HIFA EBM-2 (supplemented with hydrocortisone, 
ascorbic acid and GA-1000 (gentamicin-
amphotericin) according to manufacturer’s 
instructions:  
10 ng/mL human recombinant fibroblast 
growth factor (FGF)/carrier free, R&D 233-
FB-025  
10 ng/mL insulin growth factor (IGF)/carrier 
free, R&D 8335-G1-200 
 
2.1.2 General reagents  
 
Reagent Supplier 
Human fibronectin (0.1%) Sigma-Aldrich, F0895 
Bovine type I collagen (2.8 mg/ml) Advance BioMatrix, 5409 
Bovine gelatin (2%) Sigma-Aldrich, G1393 
Trypsin-EDTA (0.05%) Life technologies, 25300-062 
Dulbecco’s Modified Eagle’s 
Medium/Nutrient Mixture Ham’s F-12 
(DMEM/F-12) + 10% Fetal Bovine Serum 
(FBS) +1% Penicillin Streptomycin (P/S)  
Sigma-Aldrich, D8062 
Ammonium persulphate (APS) Sigma-Aldrich, A3678 
Acrylamide: bisacrylamide (37.5:1, 30% 
(w/v) acrylamide 
Bio-Rad, 161-0158 
Amersham ECL western blotting detection 
reagents 
Promega, W1015 
Amersham Hyperfilm GE healthcare, 28-9068-44 
N,NM’N’- tetramethyl ethylenediamine 
(TEMED) 
Fisher Scientific, BP150-20 
Immobilon-P polyvinyl fluoride (PVDF) 
membrane 
Merck Millipore, IPVH00010 
4’,6-diamidino-2-phenylindole (DAPI) Life technologies, D21490 
1,4-diazabicyclo[2.2.2]octane (DABCO) Sigma-Aldrich, D2522 
Mowiol 4-88 Calbiochem, 475904 
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Triton X-100 (0.2%) Sigma-Aldrich X100 
Sodium borohydride Sigma-Aldrich 452882 
Bovine serum albumin (BSA) Sigma-Aldrich, A9647 
 
2.1.3 General solutions and buffers 
 
Solution/Buffer Components 
10 x Phosphate-buffered saline (PBS) 27 mM KCL  
1.4 M NaCl,  
18 mM KH₂PO₄,  
100 nM Na₂HPO₄,  
pH 7.4. 
10x Tris-buffered saline (TBS) 50 mM Tris Base 
140 mM NaCL 
pH 7.6 
10 x SDS-PAGE running buffer 192 mM glycine 
25 mM Tris  
1.0% (w/v) SDS 
1x Transfer buffer  25 mM Tris 
192 mM glycine  
pH 8.5 
Blocking solution 5% (w/v) dry skimmed milk 
1x TBS-T 
2x Laemmli sample buffer 25 mM Tris-HCL pH 6.8 
2% (w/v) SDS 
10% (v/v) glycerol 
0.2% (w/v) bromophenol blue 
20 mM DTT 
Tris buffered saline – Tween (TBS-T) 1L TBS 
0.1% Tween 20 (Sigma Aldrich, P1379) 
 
2.1.4 Antibodies  
 
(IB: Immunoblotting, IF: Immunofluorescence) 
Primary Antibody Species Application/Dilution Supplier 
PPFIA1 Rabbit IB-1:1000 Protein Tech, 14175-1-AP 
Tubulin Mouse IB-1:5000 Sigma-Aldrich, T5168 
VE-cadherin Mouse  IF-1:200 BD Biosciences, 55-7H1 
EDA-fibronectin Mouse  IF - 1:200 Santa Cruz, sc-59826 
Fibronectin Rabbit  IF - 1:400 Protein Tech, 15613-1-AP 
Zonula Occludens-1 Rabbit IF - 1:400 Thermofisher, 61-7300 
 
Secondary antibodies Species Dilution Supplier 
Anti-mouse HRP Donkey IB: 1:10000 Jackson, 715-035-150 
Anti-rabbit HRP Donkey IB: 1:10000 Jackson, 711-035-152 
Mouse Alexa Fluor 594 Donkey IF: 1:400 Invitrogen, A21203 




2.1.5 siRNA oligonucleotides 
Target Gene  Sense strand (5’-3’)  
PPFIA1  siRNA A: AGUUUAGACCAAAGGACAUUCGUGG  
siRNA B: GCAUGACCUCAAUGAUAAACUUGAA  




Simvastatin, 98% Acros Organics, 458840010 




























2.2 Cell Biology 
 
2.2.1 Mammalian cell culture  
 
HUVEC were obtained from Lonza (CC-2519, pooled donors), and maintained in Endothelial 
Growth Medium (EGM-2, CC-3162, Lonza) and incubated at 37 °C in 5% CO2. HUVEC were 
split after reaching approximately 80% confluency. To do this, the medium was removed, and 
cells were washed twice in PBS before incubation with Trypsin-EDTA (approximately 1/10th of 
media volume) at 37 °C until detached. DMEM/F12 + 10% FCS was added at a 4:1 ratio with 
Trypsin-EDTA to neutralise the trypsin. Cells were centrifuged at 400x g for 3 minutes, before 
the pellet was resuspended in EGM-2 media, and cells were counted using a 
haemocytometer. HUVEC were generally used for experiments between passage 2 and 6. 
 
2.2.2 Coating of tissue culture dishes 
 
Prior to plating, tissue culture dishes were coated with fibronectin at a concentration of 10 
μg/mL in PBS for 30 min at room temperature. Glass coverslips were coated with fibronectin 
at the same concentration in tissue culture dishes. Transwell (Costar, 3460) inserts were 
coated with a triple coat of 100 µl PBS, 5 µl gelatin, 5 µl fibronectin and 1 µl collagen per well 


















2.3.1 Preparation of materials 
 
2.3.1.1 siRNA transfection 
 
HUVEC were cultured onto tissue culture dishes as in 2.2.1. Cells were seeded at 7 x 104 /mL 
onto dishes and incubated at 37°C 5% CO2 (v/v). After 24 hours cells were washed three times 
in room temperature OptiMEM I reduced serum medium (Gibco, 31985-047), and following  
the third wash samples were resuspended in half the normal volume. SiRNA transfections 
were made up as according to the table below. 
 Tube A Tube B 
Dish/Plate OptiMEM (µl) 20 µm siRNA (µl) OptiMEM (µl) GeneFECTOR (µl) 
12 – well plate 48.5 1.5 47 3 
6 – well plate 97 3 94 6 
6 cm dish 242.5 7.5 235 15 
10 cm dish 485 15 470 30 
  
siRNA transfections were carried out using GeneFECTOR (Venn Nova, R-0001-01) according 
to the manufacturer’s instructions. Three siRNA oligonucleotide duplexes targeting liprin-α1 
were synthesized by Origene Technologies (Herford, Germany), and a control siRNA duplex 
(#SR30004). Tube A was added to Tube B before incubating at room temperature for 5 
minutes. The mixture was then added dropwise to cells whilst swirling plates, and plates were 
incubated at 37°C 5% (v/v). After 3 hr, cells were refreshed with EGM-2, before being 
incubated at 37°C 5% CO2 (v/v) for 48 prior to experimental use. 
 
2.3.1.2 Statin preparation 
 
Statins were made up to a 1 mM solution by dissolving the statin powder in DMSO and 
stored at – 20°C until use. 
 
2.3.2 Western Blotting 
 
2.3.2.1 Sample preparation 
 
HUVEC were plated onto 6 cm tissue culture dishes as in 2.2.1. After 48 hours, cells were 
washed in PBS at room temperature, then ice cold PBS before 200 µL of 2x Laemmli lysis 
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buffer was added. After 2 minutes, cells were scraped and transferred to a centrifuge tube, 
and spun for 10 minutes at 10000x g. The supernatant was collected, and the pellet discarded. 
 
 
2.3.2.2 Sodium-dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)  
 
Gels were typically made using a 10% resolving gel and a 6% stacking gel. Resolving gels 
were prepared using 30% acrylamide/0.8% bis-acrylamide, 10% SDS, H2O, 1M Tris (pH 8.8) 
as according to the table below. TEMED and 10% APS were added just prior to pouring gel. 
The resolving gel was poured between two glass plates leaving enough space for the stacking 
gel, and overlaid with H2O, before being allowed to set at room temperature until set. The 
stacking gel was creating using 30% Acrylamide/0.8% bis-acrylamide, 10% SDS, H2O, 1M 
Tris (pH 6.8) as according to the table below. Just before pouring, 10% APS and TEMED was 
added. The resolving gel overlay was removed, and the stacking gel was added on top of the 
resolving gel between the glass plates, and an appropriate comb was inserted. After 
polymerisation of the gel the comb was removed. Samples were heated to 95 °C for 5 min, 
then loaded onto the gel. Samples were electrophoresed at 10 mA until the bromophenol blue 
entered the separating gel, when the voltage was increased to 150 volts.   
 
 Resolving gel (10%) Separating gel (6%) 
Stocks Volume Volume 
30% acrylamide/ 0.8% bis-acrylamide 5 mL 667 μL 
1M Tris-Cl  5.625 mL (pH 8.8) 625 μL (pH (6.8) 
10% SDS 150 μL 50 μL 
H2O 4.05 mL 3.6 mL 
10% APS 150 µL 50 μL 
TEMED 8 μL 5 µL 
 
 
2.3.2.3 Western blotting 
 
An Immobilon-P polyvinyl fluoride (PVDF) membrane was activated by placing in methanol for 
20 seconds, then equilibrated in the transfer buffer for 10 minutes. The PVDF membrane was 
placed onto a layer of a filter paper then fibre pad, and the SDS-PAGE gel was placed on top 
and covered by filter paper then a fibre pad. This was then placed in a gel cassette holder. 
Cassettes were placed into a Bio-Rad Mini Trans-Blot electrophoretic transfer unit with cooled 
Western transfer buffer for 1 hr at 50 V at 4°C. After transferring, the cassette was 
disassembled, and the membrane was rocked gently for 1 hr in 20 ml 5% blocking solution, 
then washed in 1x TBS-T. The membrane was then incubated in the primary antibody in 
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blocking solution overnight at 4°C on the rocker, then rinsed twice in TBS-T, before washing 
on the rocker three times in TBS-T. The membrane was then incubated with the secondary 
HRP-conjugated antibody in blocking solution for 1 hr 30, then again rinsed twice in TBS-T 
before washing three times in TBS-T on the rocker. The TBS-T was drained before covering 
with ECL reagents before incubation for 5 min at room temperature. Signal was detected by 
exposure to Hyperfilm for an appropriate amount of time based on signal strength.  
 
2.3.3 Permeability assay 
 
2.3.3.1 siRNA Transwell culture 
 
Nine hours after siRNA transfection on tissue culture dishes, HUVEC were passaged onto 
Transwell inserts at 2x105/mL. After 24 hours, the media was removed from the Transwell 
lower chamber and washed with PBS, and then from the upper chamber and washed in EBM-
2 three times. After the third wash, all media was removed from the lower and upper chambers 
and refreshed with HIFA. 
 
2.3.3.2 Statin Transwell Culture 
 
Cells were cultured on Transwell inserts as in 2.2.1 at 2x105/mL.  After 24 hours, the media 
from the lower compartment was removed was washed with PBS, and then from the upper 
chamber and washed in EBM-2, which was repeated three times. After the third wash, all 
media was removed from the lower and upper chambers and refreshed with HIFA, and 50 µl 
of statin:DMSO solution was added to the upper Transwell chamber at the required 
concentrations, and 130 µl of the same concentration was added to the lower chamber, and 
again after 24 hours. Statins were made up to a 1 mM solution in DMSO and diluted 
accordingly. 
 
2.3.3.3 Addition of FITC-dextran 
 
After incubation in HIFA for 24 hours, 20 µl of fluorescein isothiocyanate-dextran (Sigma-
Aldrich, FD40S) was added at a final concentration of 1 μg/mL to the upper compartment of 
the Transwell at a final concentration of 1 μg/mL. At 24 hours after addition, 50 µl of medium 
from the lower compartment was diluted in 950 µL PBS, and 100 µL of the solution was added 
49 
 
into a black 96 well plate. The absorbance was measured in a fluorimeter at 480 nm excitation, 
520 nm emission and 67 gain using Tecan Infinite m200 i-control fluorometer. 
 
2.3.4 Mass spectrometry  
 
2.3.4.1 Mass spectrometry 
 
HUVEC were cultured onto Transwell inserts at 2 x 105 cells per insert, and after 24 hours 
refreshed with HIFA as according to 2.2.1. After 48 hours, conditioned media from the upper 
and lower compartment of the Transwell inserts was transferred to separate microfuge tube 
and the media from the upper compartment of the Transwell was made up to 1.3 mL using 
HIFA. The samples were then centrifuged at 300 x g for 5 minutes at 4°C to remove any cells 
present, and media was transferred to a fresh centrifuge tube. Aliquots of the media were then 
transferred to separate Amicon Ultra 0.5 mL centrifugal filters (Merck Millipore, R8HA86271), 
and centrifuged at 16400x g for 15 minutes at 4°C, and filtered media was discarded. After 
concentration of media inside the filter to about 50 μL, filters were reverse centrifuged at 1000x 
g for 2 minutes into a fresh microfuge tube to allow the proteins to be eluted. Samples were 
kept on ice between steps. 
 
2.3.4.2 Proteomic analysis 
 
Proteomic analysis was performed by Dr Kate Heesom of Bristol Proteomics Facility. An equal 
volume of each sample was digested with trypsin and then labelled with Tandem Mass Tag 
(TMT) ten plex reagents according to the manufacturer’s protocol (Thermo Fisher Scientific.  
The labelled samples were pooled and analysed by nano-LC MSMS using an Orbitrap Fusion 
Tribrid Mass Spectrometer.  The raw data files were processed and quantified using Proteome 
Discoverer software v1.4 (Thermo Scientific) and searched against the UniProt Human 
database using the SEQUEST algorithm.  Peptide precursor mass tolerance was set at 
10ppm, and MS/MS tolerance was set at 0.6Da. Search criteria included oxidation of 
methionine (+15.9949) as a variable modification and carbamidomethylation of cysteine 
(+57.0214) and the addition of the TMT mass tag (+229.163) to peptide N-termini and lysine 
as fixed modifications. Searches were performed with full tryptic digestion and a maximum of 
1 missed cleavage was allowed.  The reverse database search option was enabled, and all 






Cells were transfected with siRNA as described in 2.3.1 and were cultured on Transwell inserts 
as described in 2.2.1. After 24 hours, the media was removed from the Transwell lower 
chamber and washed with PBS, and then from the upper chamber and washed in EBM-2 three 
times. After the third wash, all media was removed from the lower and upper chambers and 
refreshed with HIFA. 48 hours after seeding onto Transwell inserts, all media was removed 
from both the lower and upper chamber of the Transwell, and the media from the upper 
compartment was made up to 1.3 mL using HIFA. Reagents and samples were prepared as 
according to the R&D human fibronectin Quantikine ELISA kit (R&D, DFBN10) sandwich 
enzyme immunoassay technique. 100 µL of assay diluent was added to each of the wells, and 
50 μL of the standard, control, or sample was added to each well. The plate was covered with 
a plate seal and incubated on a horizontal orbital microplate shaker at room temperature for 2 
hours. Each well was then aspirated and washed with the provided ELISA wash solution four 
times. After adding 200 µL of the provided conjugate to each well, the plate was covered with 
a new plate sealer, and incubated at room temperature for 2 hours on the shaker. After again 
aspirating and washing four times, 200 µL of the provided Substrate Solution was added to 
each well and the plate was incubated at room temperature in the dark for 30 minutes. After 
this time, 50 µL of the provided Stop Solution was added to each well, and the plate was read 
at 450 nm with a wavelength correction of 540 nm. A standard curve was created using the 
provided fibronectin standard, to allow concentrations of fibronectin to be determined. 
 
2.3.6 Immunofluorescence microscopy 
 
Cells were seeded onto Transwell inserts at 2 x 105 cells/mL, or glass coverslips at 1 x 
105/mL as according to 2.2.1 and incubated at 37 °C overnight. After this, the growth media 
was removed, and samples were washed three times in PBS, before 4% (w/v) 
paraformaldehyde (PFA, Fisher Scientific, 30525-89-4)/PBS was added to samples for 15 
minutes to fix the samples, then removed. Samples were washed twice with PBS before 0.2% 
Triton was added to permeabilise the cells, and samples were incubated at room temperature 
for 5 minutes before washing three times in PBS. 0.1% sodium borohydride solution was then 
added for 5 minutes at room temperature to quench autofluorescence, before incubating, 
before samples were washed three times in PBS. Samples were then incubated with 1% BSA 
for 20 minutes, before 30 µL of the primary antibody:BSA solution was added to the Transwell 
insert for 1 hr. Cells were then washed three times in PBS, and 30 μL of the secondary 
antibody:PBS solution was added to the Transwell and incubated for 45 minutes in the dark 
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at room temperature. If coverslips were used, the protocol was followed the same until addition 
of the primary antibody, where coverslips were inverted onto 80 μL of the primary 
antibody:BSA solution and incubated at room temperature for one hour, before washing three 
times in PBS. Coverslips were then again inverted onto 80 μL of the secondary antibody:PBS 
solution for 45 min. Samples were washed twice in PBS to remove the secondary antibody, 
then DAPI (1:5000) was added and samples were incubated at room temperature for 5 
minutes. For Transwell inserts, cells were washed four times in PBS, and the Transwell 
membranes were excised using a blade, and were mounted onto glass slides using 5 µL 
of Mowiol mounting solution containing 2.5% (w/v) DABCO.  Slides were left to dry overnight 
in the dark at room temperature, and then stored at 4°C in the dark. If using glass coverslips, 
cells were washed four times before 5 μL of Mowiol mounting solution containing 2.5% (w/v) 
DABCO was added to the slide before coverslips were inverted onto slides. Images were taken 
using a Leica SP5-AOBS confocal laser scanning microscope attached to a Leica DM I6000 
inverted epifluorescence microscope.   
 
2.4 Statistical analysis 
 
Wherever possible, a minimum of three biological repeats were performed for each experiment 
with the appropriate controls. Quantitative data was expressed as mean +/- SEM and P-values 
were calculated using the appropriate statistical test, typically a one-way ANOVA with 
repeated measures, with a Dunnett’s multiple comparison post hoc test, unless specified in 
the Figure legend. A P-value of <0.05 was considered statistically significant. The statistical 














Chapter 3 The HUVEC polarised secretome 
 
3.1 Introduction  
 
Currently, there are few studies that have analysed the proteome of endothelial cells (ECs), 
and fewer still that have analysed the secretome of ECs [167]. It is well known that ECs are 
polarised and therefore have different secreted proteins at their apical and basal surfaces; 
however previous studies have only focused on the entire secreted proteome [167]. Transwell 
permeable supports enable the separation of apical and basal conditioned media and 
therefore of the proteins secreted from each surface, allowing them to be individually analysed. 
This technique allows the user to gain an insight of the difference in the protein secretion from 
each surface to allow a deeper understanding of the role of ECs. 
The polarised secretome of ECs relies on the different intracellular transport mechanisms of 
vesicles to the cell surface membrane, allowing different proteins and in different amounts to 
be secreted separately from the apical and basal surface. The apical and basal membrane 
differ in their lipid and protein composition, allowing the polarised transport and secretion of 
molecules [168].  
Recent studies have focussed on the polarised secretion of fibronectin (FN) in ECs, a 
glycoprotein involved in the extracellular matrix (ECM) of cells. FN is transported along 
microtubules to the basolateral surface, where it is then secreted to form part of the ECM in 
confluent human umbilical vein ECs (HUVEC) [33]. Whilst there has been little data on the 
regulation of polarised protein secretion by ECs, recent studies have shown that knocking 
down liprin-α1, a protein involved in microtubule docking at the cell periphery, disrupts the 
transport of FN to the basolateral surfaces of ECs [35]. To explore the function of liprin-α1, I 
used siRNA mediated silencing to deplete expression of the protein, to allow an insight in to 
whether other proteins that are transported to the basolateral surface by this mechanism. The 
dysregulated secretion of FN is of clinical significance, as it is implicated in diseases such as 
atherosclerosis [169]. FN is one of the earlier ECM proteins that is deposited at the sites of 
atherosclerosis plaque sites, and may promote plaque formation [170].  
My study used HUVEC, obtained from the major vein of human umbilical cord, which is 
otherwise discarded after childbirth. These primary cells are the most commonly used ECs 
when modelling ECs in vitro, as in early passages retain their physiological and morphological 
properties [171]. HUVEC provide an ideal model system, allowing the investigation of many 
aspects of endothelial function and disease. ECs are involved in a large variety of different 
functions, such as angiogenesis and blood coagulation, and these processes can, as well as 
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being viewed under normal conditions, be manipulated to induce disease states for medical 
research purposes [7]. 
My research had three objectives 
1) To investigate the normal polarised secretome of HUVEC 
2) To examine the polarised secretion of FN with liprin-α1 siRNA, to compare results with 
the study by Mana et al (2016) in the paper ‘PPFIA1 drives active α5β1 integrin 
recycling and controls fibronectin fibrillogenesis and vascular morphogenesis’ 
3) To use liprin-α1 siRNA to decrease expression of liprin-α1 in HUVEC, and to explore 
whether any proteins of the normal polarised secretome are affected 
These investigations will give a deeper insight into the mechanisms involved in EC secretion. 
The data provided by the mass spectrometry will give insight into other proteins secreted via 
the same pathway as FN. Like FN, some of these proteins could also be implicated in disease, 




















3.2.1 Analysis of the HUVEC secreted proteome 
 
In order to successfully study the polarised secretion of ECs, there needs to be a separation 
of the apical and basal layer. For all the experiments on the secretion of proteins in my 
experiments, Transwell inserts are used in order to separate the medium, and therefore the 
secreted proteins. Transwell inserts are permeable supports, that allow cells to be cultured 
upon their surface. Small molecules are able to pass through the 0.4 µm pores within the 
support from the apical surface to the basal media, and vice versa. The pores within the 
permeable membrane inserts allow protein secretion from the basal surface to pass through 
to the basal chamber, whilst EC monolayer prevents leakage of apical proteins. 
In order to investigate the polarised secretion of protein, mass spectrometry of the conditioned 
media of the separate apical and basal compartment was performed. These samples were 
prepared for mass spectrometry by Dr Haoche Wei. The samples were obtained by extracting 
the media from the upper compartment and transferring to a centrifuge tube, and the same 
with the media from the lower compartment (Figure 3.1A). The media from the upper 
compartment was diluted to the same volume as the lower compartment, by the addition of 
HIFA (Figure 3.1A). The data obtained from this study was then given to me by Dr Wei, for my 
own analysis. 
I firstly analysed this data to gain an initial understanding of the polarised secretion of ECs. I 
calculated the ratio of apical/basolateral secretion and used a log2 transformation of these 
values (Figure 3.1B). Proteins which were apically polarised, where a higher amount protein 
was secreted from the apical surface of the EC than the basolateral surface, would have 
positive log2 values. Proteins which were basolaterally polarised, where a higher amount of 
the protein was secreted from the basolateral surface than the apical would have a negative 
log2 value. I found that the secretion of the majority of proteins within my data were apically 
polarised. 
I performed further analysis of the secreted proteome of HUVEC, by plotting the 
apical/basolateral ratio of the protein against the P-value (Figure 3.2A). In this analysis, P-
values were calculated by comparing the apical/basolateral ratio of protein secretion against 
the assumption that there was no polarisation, with the value 1.  P-values indicate the 
significance of results, and P-values below a certain value (typically 0.05) are classed as being 































Figure 3.1 Analysis of the HUVEC secreted proteome. A) The media was collected from 
the upper and lower compartment of the Transwell, and the upper compartment was made up 
to 1.3 mL using HIFA. The media was then centrifuged using ultra centrifugal filters until 
concentrated to 50 μL, and then analysed by mass spectrometry. B) The distribution of 
proteins secreted from the apical membrane and the basal membrane, shown by plotting the 
data on a log2(apical/basolateral) scale graph. Proteins with a positive log2 value were 
secreted apically, and proteins with a negative log2 value were secreted from the basal 
membrane. The majority of the proteins were secreted apically.  
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Figure 3.2 HUVEC display polarised secretion. A) Further analysis of the proteome by 
volcano plot of the ratio of apical/basolateral against the P-value achieved. Values above 1 
on the x-axis are polarised apically, and values below 1 are polarised basolaterally. P-values 
below 0.05 were considered be statistically significant. Proteins of interest which were known 
to be secreted and have significant P-values have been highlighted and are marked pink 
within the graph. B) The table contains known secreted proteins that have been shown to be 
important from the volcano plot which notably change their polarization with liprin-α1 
depletion. The corresponding data point in the volcano plot has been highlighted in pink.  
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were analysed using UniProt, and those known to be secreted and with significant P-values 
on the graph were marked pink (Figure 3.2A). The proteins corresponding to these points are 
shown in Figure 3.2B. The proteins which are polarised basally are generally components of 
the ECM (Figure 3.2B). The protein collagen α1 is basolaterally polarised with an 
apical/basolateral ratio of 0.8745, and P-value of 0.00126 (Figure 3.2B). Collagen α1 is a 
protein which forms part of the ECM, a network of certain proteins that provides structural and 
biochemical support to the ECs [26]. The other secreted proteins basolaterally polarised 
include perlecan and FN, which are both other known components of the ECM (Figure 3.2B) 
[26]. However, other known components of the ECM including nidogen and laminin subunit γ1 
are both shown to be polarised apically (Figure 3.2B). My study showed that laminin subunit 
γ1 had a significant P-value of 0.025075, suggesting it is significantly apically polarised, 
however other studies have found that laminin is not secreted apically in corneal ECs [172].  
From the proteins found to have a significant P-value in the volcano plot in Figure 3.2, these 
proteins were further analysed to see which proteins were true secreted proteins by analysis 
using UniProt (Figure 3.3). These proteins were then subdivided into their function and shown 
in the pie-chart (Figure 3.3A). Almost 70% of the proteins are those involved with the ECM, 
such as the protein perlecan, a large proteoglycan that is involved in cross linking the ECM 
and other cell surface molecules [173]. Other secreted proteins with significant P-values 
include the enzyme lysyl oxidase homolog 2, which is basolaterally polarised. Lysyl oxidase 
homolog 2 is involved in crosslinking collagen type IV in the basement membrane, and 
involved in the regulation of angiogenesis [174]. Other secreted proteins were found to be 
involved in the binding of growth factors, and angiogenesis (Figure 3.3A). The secreted 
proteins and their corresponding ratios and P-values are shown in Figure 3.3B.   
 
3.2.2 Transfection of HUVEC with Liprin-α1 siRNA can affect monolayer permeability 
 
In order to gain accurate data about the polarised secretion of proteins, the HUVEC monolayer 
must have high integrity, showing strong cell-cell junctions in order to ensure proteins cannot 
freely pass between the cells. One way to measure the integrity of the HUVEC monolayer is 
by the addition of fluorescein isothiocyanate (FITC)-dextran, a fluorescent probe that can pass 
through the HUVEC monolayer. If the cell-cell junctions of the HUVEC are poor, more FITC-
dextran will be able to pass through the monolayer. This means when the fluorescence of the 
lower compartment is measured by fluorescence absorbance spectrometry, the result will be 
higher than if the monolayer junctions are well maintained. Ideally, the HUVEC will form a 


















Figure 3.3 Function of proteins identified in the HUVEC secretome Analysis of 
secretome identified using TMT mass spectrometry was performed using UniProt 
(www.uniprot.org). The table shows the secreted proteins with their corresponding ratios and 





the confluent monolayer will reduce the likelihood of proteins being able to diffuse through the 
cell monolayer, which could cause incorrect polarised secretion values. By exploiting the traits 
of the Transwell, I was able to effectively measure the permeability of the monolayer. After 48 
h of culture on Transwell insert, FITC-dextran was added to the upper chamber of the 
Transwell (Figure 3.4). Following 24 h after FITC-dextran addition, media was removed from 
the lower chamber of the Transwell, and the media transferred into a well of the 96 well plate 
before the fluorescence intensity of the media was read and presented as an absorbance 
value (Figure 3.4). 
My assay found that the permeability of HUVEC was not significantly affected by transfection 
with liprin-α1 siRNA C or the control siRNA (Figure 3.5A). However, transfection of HUVEC 
by liprin-α1 siRNA B caused a statistically significant increase in permeability of the HUVEC 
(Figure 3.5A), with a P-value of 0.0009. 
In order to support these permeability values and investigate the integrity of the cell 
membranes, HUVEC were transfected with liprin-α1 siRNA and seeded onto glass coverslip 
for 48 h before fixing and staining for ZO-1 and VE-cadherin. ZO-1 is a component of tight 
junctions, and VE-cadherin of adherens junctions, two of the main junctions in ECs which are 
important in maintaining vascular integrity [175,176]. In comparison to the control, HUVEC 
transfected with liprin-α1 siRNA C showed no noticeable difference in the distribution of these 
proteins (Figure 3.5B).  Using the data gained in this experiment, as well as the permeability 
data in the liprin-α1 siRNAs (Figure 3.5A), I was able to confidently use liprin-α1 siRNA C for 
the mass spectrometry experiments as it did not have a significant effect on the permeability. 
 
3.2.3 Liprin-α1 controls the sorting of a subset of proteins to the basolateral surface 
 
Liprin-α1 is a part of the cortical microtubule stabilising complex, which localises microtubules 
to focal adhesions. Mana et al (2016), showed that the protein PPFIA1, which is also known 
as liprin-α1 was responsible for the recycling of the integrin α5β1. This integrin is trafficked 
with FN, a protein which forms part of the ECM, suggesting that liprin-α1 is involved in the 
trafficking of FN to the basolateral surface of the cell. Mana et al (2016) showed that by 
suppressing the expression of liprin-α1 the secretion of ED-A FN, the endogenous FN 
secreted by ECs, is severely impaired [35]. 
A key stage in the formation of an atherosclerotic plaque is the expansion of the ECM, and FN 









(total volume 1.3 mL) 
Upper compartment 
(total volume 0.5 mL) 
24 hours 




Add 20 μL of FITC-
dextran to upper 
compartment  
Remove 50 μL of 
media from the lower 
compartment 
Dilute 50 μL media in 950 
μL PBS 
100 μL of each 
condition is added into 
separate wells to be 
read by a plate 
scanner to measure 
absorbance  
Figure 3.4 Method of obtaining permeability data. After being cultured for 48 hours on 
Transwell inserts, 20 μL of FITC-dextran is added to the upper compartment of the Transwell 
insert. 24 hours after addition, 50 μL of media from the lower compartment is diluted in 950 
μL PBS. 100 μL of this solution is added into a well of the 96 well plate, of which the 










































Liprin-α1 siRNA B Liprin-α1 siRNA C Control 
Figure 3.5 Liprin-α1 siRNAcan affect HUVEC monolayer A) Liprin-α1 siRNA C showed 
no significant difference in permeability compared to the control, whilst siRNA B showed a 
statistically significant difference (P-value = 0.0009). Permeability experiments were 
performed by culturing transfected HUVEC onto Transwell inserts for 48 hours, before 
adding FITC-dextran to the apical compartment. The fluorescence absorbance of the 
media from the lower compartment was measured after 24 hours. Statistical analysis 
performed using a one-way ANOVA and Dunnett’s multiple comparison post hoc test and 
P-values below 0.05 were considered to be statistically significant. Graphs are plotted as 
means ± SEM (n=4), and data is normalised to the control. B) Liprin-α1 siRNA were 
transfected 24 h prior to seeding onto coverslips, and control mock transfected HUVEC 
were seeded at the same time. After a further 48 h the cells were fixed and stained for ZO-
1 and VE-cadherin. Cells were then imaged using confocal microscopy. Liprin-α1 siRNA 
transfected cells show a slight difference in ZO-1 and VE-cadherin distribution in 
comparison to the control, especially liprin-α1 B. Arrows show differences in distribution of 
















































levels of FN have been found in atherosclerotic regions [169]. ED-A FN, a variant of FN that 
contains an extra A domain, is a form of FN has been suggested to support atherogenesis, 
the formation of arterial fat deposits, and high levels of ED-A FN are seen during 
atherosclerosis [169]. Impaired blood flow, which occurs in plaque formation causes the 
deposition of FN by ECs into the vessel wall [169]. As one of the leading causes of death in 
the western world, this disease and its contributing factors, including FN deposition are of high 
clinical importance [169,178]. High levels of ED-A FN are seen in the plasma samples of 
patients at high risk of developing coronary artery disease, including atherosclerosis 
compared with the low levels seen in patients at low risk, and this high level is believed to be 
involved in inflammation and disease progression [177]. 
Figure 3.6A shows the mechanism of FN trafficking from the synthesis of FN dimers in the 
trans-Golgi network (TGN) to the basolateral membrane. Upon leaving the TGN, FN dimers 
are transported to trans Golgi carriers, associated with the integrin α5β1 to the cell membrane 
where it is exocytosed (Figure 3.6A). Liprin-α1 is an adaptor protein that forms part of the 
cortical microtubule stabilising complex, which is involved in the tethering of microtubules to 
the membrane and localises them close to focal adhesions (Figure 3.6B). 
To further explore the function of liprin-α1, siRNA mediated silencing was used to decrease 
expression of liprin-α1. HUVEC were cultured and transfected with liprin-α1 siRNA. Figure 
3.7A shows a Western blot of the expression of liprin-α1 within the HUVEC. Each of the liprin-
α1 oligonucleotide duplexes gave significant depletion of the protein, with liprin-α1 siRNA B 
and liprin-α1 siRNA C showing the highest depletion at 97% (Figure 3.7A). These two siRNAs 
were then used for subsequent experiments. 
Following on from the study by Mana et al (2016), I analysed the effect of liprin-α1 depletion 
on the secretion of FN using ELISA. By culturing liprin-α1 siRNA transfected HUVEC on 
Transwell polyester membrane inserts, the apical and basolateral conditioned medium, and 
therefore the polarised secretion of ED-A FN could be separated. My data showed that, 
supporting the data by Mana et al (2016), the suppression of liprin-α1 led to the decreased 
basolateral secretion of FN (Figure 3.7B). I showed that the basolateral secretion of ED-A FN 
was strongly impaired by the depletion of liprin-α1, however, the apical secretion is not affected 
in confluent cultured HUVEC (Figure 3.7B). This result was also seen by Mana et al (2016) in 
their ELISA. 
To investigate whether the depletion of liprin-α1 affected any other proteins, I used mass 
spectrometry. Transfected HUVEC were cultured on Transwell inserts for 48 hours, then the 
apical and basal condition media was removed and prepared for mass spectrometry. Liprin-





































Figure 3.6 Liprin-α1 localises to focal adhesions, by binding directly to the β1 tail of 
integrins. A) Mechanism of fibronectin transport to the basolateral surface of ECs. Figure 
adapted from supplementary figure by Mana et al (2016).  B) Liprin-α1 forms part of the 
microtubule stabilising complex to anchor microtubules at the basolateral surface. Figure 
















































Figure 3.7 Liprin-α1 affects the polarised secretion of fibronectin from the 
basolateral surface. A) Liprin-α1 siRNA showed significant depletion of liprin-α1 (94%, 
97% and 97% respectively) in comparison to the control. Analysis was performed 48 hours 
after transfection of HUVEC using western blot, and silencing calculated using ImageJ. B) 
The literature showed that Liprin-α1 siRNA decreased the polarised secretion of fibronectin 
from the basolateral surface, and analysis of fibronectin secretion was performed using 
ELISA. Control HUVEC were seeded directly onto Transwell inserts. Liprin-α1 siRNA B 
and C HUVEC were transfected before seeding onto Transwell inserts. Media from the 
upper and lower compartment of the Transwell insert was collected from each of the 
conditions and analysed using ELISA. A – Apical secretion, B – Basolateral secretion. The 
silencing of liprin-α1 using siRNA was shown to strongly decrease the secretion of 
fibronectin in the basolateral secreted media of the siRNA transfected HUVEC in 







of liprin-α1 in HUVEC. Generally, the depletion of liprin-α1 by siRNA did not affect the polarised 
secretion of proteins (Figure 3.8A). R2 values are a statistical measure of how well the data  
fits a regression line, with a higher R2 value meaning that a high amount of the secreted 
proteins in the liprin-α1 siRNA transfected HUVEC sample show the same secretion ratio as 
the proteins in the control HUVEC, and a lower R2 value showing that few of the secreted 
proteins in the liprin-α1 siRNA transfected HUVEC show the same secretion ratio as the 
secreted proteins within control HUVEC. With an R2 value of 0.7691, the relationship between 
the control HUVEC and liprin-α1 siRNA transfected HUVEC shows a strong correlation 
between the ratio of proteins secreted both by liprin-α1 siRNA transfected HUVEC and control 
HUVEC, showing generally liprin-α1 does not control secretion of proteins from the basolateral 
membrane (Figure 3.8A). Particular proteins affected by the depletion of liprin-α1 are 
highlighted in pink in Figure 3.8A, and their corresponding ratio for both the control HUVEC 
and liprin-α1 siRNA transfected HUVEC are shown in Figure 3.8B. Most of the proteins which 
are affected by liprin-α1 siRNA transfection are proteins which are secreted basolaterally by 
ECs into the ECM, including collagen I α1 and α2, and nidogen-1. In the control HUVEC, these 
proteins were apically polarised, whilst in the liprin-α1 transfected siRNA these became more 
basolaterally polarised. This data conflicts current understanding of these proteins, as 
previous studies have found these proteins were secreted into the ECM [31]. However, the 
control sample only had one repeat, in comparison to the three repeats of the liprin-α1 siRNA 
transfected HUVEC, meaning any differences between the control samples could not be seen 
and a mean could not be taken. To verify this further, a repeat of the mass spectrometry with 
more samples of the control would need to be performed. Included in the table in Figure 3.8B 
are the ratios of FN, both in the control and in the liprin-α1 siRNA transfected HUVEC, which 
is highlighted in yellow in Figure 3.8A. Compared to the data obtained by my ELISA (Figure 
3.7B) where the basolateral secretion of FN decreased noticeably, the change shown in my 
mass spectrometry is not as noticeable. 
 
3.2.4 Liprin-α1 siRNA transfection of HUVEC does not affect the distribution of EDA-FN when 
analysed using mass spectrometry 
 
The current evidence from my study provides differing results on the secretion of FN in liprin-
α1 siRNA transfected HUVEC. My ELISA data supports the paper by Mana et al (2016), and 
my mass spectrometry data showed that the secretion of FN becomes slightly more apically 
polarised with the depletion of liprin-α1. However, mass spectrometry analysis only provides 


















































Figure 3.8 Liprin-α1 siRNA affects the polarised secretion of certain proteins. A) The 
apical/basolateral ratio of the control HUVEC were calculated, and log2 values were 
plotted against the Liprin-α1 silenced apical/basolateral log2 values. An R
2 
value is a 
measure of how well the data fits the regression line, and an R
2 
value of 0.7691 shows a 
moderate positive correlation between the two conditions, suggesting that Liprin-α1 
knockdown does not affect the polarised secretion of all proteins. However, there a few 
proteins which are affected, with highlights included in the table below. Fibronectin, the 
secretion of which has previously shown to be affected by liprin-α1 silencing is highlighted 
in yellow, as the mass spectrometry data found secretion became slightly more apical in 
the polarised secretion of fibronectin. B) The table compares the ratio of the secretion of 
particular proteins, and the change liprin-α1 silencing has on the secretion. A value above 
1 means the protein is secreted more apically than basally, and a value below 1 means a 
protein is secreted more basally than apically. These proteins were highlighted as they are 
known secreted proteins and show a considerable difference in their secretion with Liprin-
α1 knockdown. The ratio of fibronectin is also shown in the table, to show there was a 
small difference in the mass spectrometry of the polarised secretion, becoming slightly 
more apically polarised. 
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try and elucidate the true effect of liprin-α1 silencing on the secretion of FN, HUVEC were 
transfected with liprin-α1 siRNA and seeded onto glass coverslips, before fixing and staining 
for ED-A FN. The distribution of ED-A FN is similar whether transfected with control siRNA 
and liprin-α1 siRNA, suggesting that the depletion of liprin-α1 does not affect EC secretion of 
ED-A FN (Figure 3.9). This conflicts with the study by Mana et al (2016), which showed using 




























Control siRNA EDA-FN  Liprin-α1 siRNA EDA-FN 
Figure 3.9 Liprin-α1 has no effect on the secretion and distribution of EDA 
fibronectin. A) HUVEC were transfected using siRNA and grown on coverslips for 48 
hours, before fixing and staining for EDA-fibronectin. Cells were then imaged using 
confocal microscopy. There was no noticeable difference in the secretion of EDA-FN 
between either of the conditions. Similar observed densities are shown with white 





Whilst polarised secretion of ECs is essential to their function, the mechanisms by which this 
sorting occurs is poorly understood. Throughout my study, I aimed to examine the role of the 
liprin-α1 in the basolateral secretion of proteins, as it had previously been shown to be involved 
in the targeted secretion of fibronectin [35]. 
Initially I analysed the polarised secretome of HUVEC, which showed that secreted proteins 
were mainly apically polarised. Using statistical analyses (one-way ANOVA and Dunnetts post 
hoc test) to generate P-values, I examined the secretome and found that the majority of 
proteins with statistically significant P-values were basolaterally polarised proteins involved in 
the ECM, such as perlecan and collagen α1. My analysis showed there are differences in the 
roles of proteins secreted from the apical and basolateral surface of ECs, with the secretion 
of ECM proteins significantly polarised to the basolateral surface of ECs. 
After analysing the normal polarised secretome of HUVEC, I investigated the polarised 
secretome of HUVEC where I had silenced the expression of liprin-α1. I initially investigated 
whether depleting liprin-α1 expression using siRNA in HUVEC affected the integrity of the 
HUVEC monolayer.  
In a non-disease state, HUVEC form a continuous cobblestone-like monolayer which lines the 
lumen of blood vessels. This monolayer acts as a selective barrier to the passage of solutes 
between the blood and the underlying tissue, whilst allowing essential small molecules such 
as ions, nutrients and water to flow across [179]. HUVEC are commonly used in experimental 
systems, due to their ability to form the so-called cobblestone phenotype, mimicking the in 
vivo phenotype of ECs [180]. 
After isolation from umbilical veins, HUVEC can be propagated by using endothelial specific 
media, supplements [180]. Coating of the membrane HUVEC are grown upon in ECM 
components such as collagen and fibronectin, promotes EC attachment [181]. During cell 
culture HUVEC form the characteristic markers of ECs, such as the polygonal shape, and tight 
and adherens junctions, responsible for integrity of the monolayer. A study by Jiménez et al 
(2013) showed that HUVEC cultured on ECM components form a tight monolayer, replicative 
of the human umbilical vein endothelium in vivo [180]. 
The integrity of the EC monolayer in vitro can be measured by several different methods, 
including by Transwell permeability assays. In this study, the passage of 70 kDa FITC-
conjugated dextran was used to measure the monolayer integrity, which has been used in 
multiple studies in the literature [179]. FITC-dextran was added to the upper chamber of the 
Transwell, and after 24 hours a sample was removed from the lower chamber, and the 
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absorbance was read in a fluorometer. The more permeable the HUVEC monolayer, the 
higher the absorbance of the media from the lower chamber will be. In this study, the HUVEC 
monolayer after treatment, by either siRNA or statin was compared a control HUVEC 
monolayer. For each independent experiment, the raw control monolayer absorbance was 
given the value 1, with the treated HUVEC absorbance value calculated relative to this. To 
support my analysis of the absorbance values, I also used immunofluorescence microscopy 
to stain for ZO-1 and VE-cadherin, both markers of endothelial cell-cell junctions. As well as 
measuring the absorbance of a control HUVEC monolayer, I could also have measured the 
passage of FITC-dextran across a blank Transwell insert. This would allow me to know the 
maximum value of transmission and allow me to be more confident with my HUVEC monolayer 
values showing integrity.  
Another method which could be used to investigate membrane integrity is by measuring the 
transendothelial electrical resistance (TEER). When HUVEC have formed a tight monolayer, 
they should resist the passage of electrical current, and provide a quick and real time 
evaluation of the monolayer [182]. The resistance of the can be measured with an ohmmeter, 
and a calculation can provide an integrity value [182]. Unlike when using FITC-dextran, where 
HUVEC were discarded after the media from the lower chamber was removed, using the non-
invasive TEER method would allow me to continue to use the cells in the same experiment. 
This would have been especially effective for my mass spectrometry experiments, as I did not 
know the integrity of the monolayer which may have had a direct impact upon my results. By 
using a TEER value, I would have known the integrity of my monolayer, which would have 
allowed me to be more confident in my results. 
If the monolayer was disrupted, proteins may be allowed to pass between gaps in the cell-cell 
junctions to the opposite media, meaning I would be unable to identify whether proteins were 
apically or basolaterally secreted. By performing both permeability assays and confocal 
microscopy I was able to select the liprin-α1 siRNA that affected the HUVEC monolayer the 
least, as shown by a lower level of FITC-dextran permeability.  
To measure the efficiency of my siRNA as depleting liprin-α1, I used a Western blot, with 
tubulin as a loading control. The purpose of a loading control is to indicate an equal loading of 
samples. However, liprin-α1 is involved in stabilising microtubules, which are formed of tubulin. 
Therefore, it is possible that the use of liprin-α1 affected the levels of tubulin inside my HUVEC, 
and therefore would appear as different intensities in my Western blot. In my Western blot (Fig 
3.7A), the level of tubulin appears decreased when HUVEC were treated liprin-α1 siRNA. This 
means the assumption that the siRNA was effective at depleting the expression of liprin-α1 at 
up to 97% may be inaccurate, as the tubulin levels appear different. Therefore, I cannot be 
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confident that the siRNA reduced the expression of liprin-α1 by levels of up to 97%, or whether 
a loading error between the controls and the siRNA occurred. In future experiments, another 
loading control such as calnexin could be used to ensure the effect on liprin-α1 levels is solely 
caused by the effects of the siRNA. 
I demonstrated in my ELISA, as in the study by Mana et al (2016), the basolateral secretion 
of fibronectin (FN) decreased with the depletion of liprin-α1 [35]. 
To investigate this further, I used mass spectrometry to find out the apical/basolateral ratio of 
secreted protein. Liquid chromatography with tandem mass spectrometry, followed by 
database interrogation is a common bioanalytical technique which is able to identify peptides, 
and their relative abundances within a sample [183].  Proteins are identified by matching their 
observed spectra to the predicted spectra of that protein. My mass spectrometry assay had 
peptide precursor mass tolerance at 10 ppm, meaning that if my precursor peak was not with 
0.01 Da of the theoretical mass, the sequence was not accepted, and disregarded in the 
analysis. This is to reduce the possibility of false positive errors, which can result in false 
protein identification [183].  My mass spectrometry also had a MS/MS tolerance of 0.6 Da, 
which allows for errors in the masses detected by the instrument, and values which do not fall 
within the limit are again excluded. However, some of the excluded values may in fact be 
correct, whilst other identified as correct, may still be false positives. These can lead to 
discrepancies between data, especially when performing multiple repeats. My experimental 
design also accounted for other possible differences, such as post-translational modifications, 
but there is still the possibility of false data. Differences in the data can also occur for other 
reasons, such as differences in preparation or loading of the samples, or contamination by 
foreign bodies.  
The mass spectrometry data obtained in this study is n=1, with three technical repeats in each. 
This means that the secretion of some proteins may have been falsely identified as being 
affected by the depletion of liprin-α1, whilst other important proteins may have been 
overlooked. This means I cannot draw any clear conclusion from my analysis. By having three 
separate biological repeats of the mass spectrometry analysis and comparing the results, the 
chance of these errors occurring would be reduced, as I would be able to identify any 
anomalous results. This would improve the validity and accuracy of my results, meaning that 
they could be used to investigate other mechanisms of polarised secretion in ECs. 
I found that the ratio of apical/basolateral secretion increased when liprin-α1 expression was 
depleted, further supporting the study by Mana et al. As well as this, mass spectrometry 
provided me with data that showed that depletion of liprin-α1 affected the sorting and delivery 
of a subset of proteins to the basolateral surface. These proteins included nidogen-1, collagen 
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α1 and collagen α2, which are components of the ECM. I found that these proteins became 
more basolaterally polarised with the depletion of liprin-α1, which could potentially be due to 
the cell being aware of the reduction of FN secretion, and therefore increasing the basolateral 
secretion of these proteins. However, I found that many other basolaterally secreted proteins 
were not affected by liprin-α1, showing there are other mechanisms of polarised trafficking 
other than the mechanism using liprin-α1.  
Whilst dysregulated secretion of FN is a known contributing factor in atherosclerosis, one 
major aim of this research was to discover the other proteins involved [184]. This research has 
provided the background for further investigations of the proteins highlighted in the mass 





























Cardiovascular disease (CVD), comprising of strokes, angina and heart attacks, is the leading 
cause of mortality in the world, attributed to over a quarter of global deaths [178,185]. One 
major risk factor for CVD events is high blood cholesterol, and therefore reducing cholesterol 
levels is of clinical importance. Statins are the first choice of treatment for reducing blood 
cholesterol and are one of the most commonly prescribed drug within the UK health system 
[186]. Statins act by inhibiting the enzyme HMG-CoA reductase, a rate-limiting enzyme 
involved in the cholesterol synthesis pathway, therefore reducing the production of cholesterol. 
Statins are structurally similar to HMG-CoA, the biological substrate for rate-limiting enzyme 
HMG-CoA reductase, so act by competitive inhibition [166]. This inhibition reduces the ability 
of HMG-CoA to produce mevalonate, the next molecule in the cholesterol cascade [166]. Most 
of the circulating cholesterol in the body is produced internally by the liver via the cholesterol 
synthesis pathway, rather than from the diet. This in turn reduces the levels of blood 
cholesterol, and thus reduces the risk of CVD events. As well as directly affecting HMG-CoA 
reductase in the liver, statins have also been shown to have pleiotropic effects, including on 
the vascular endothelium.  Previous studies have suggested that statins can affect 
endothelium vascular tone, and can inhibit inflammatory responses [187]. By inhibition of the 
HMG-CoA reductase pathway, statins also inhibit specific prenylation, the addition of 
hydrophobic prenyl group involving either farnesyltransferase or geranylgeranyl transferase, 
and the prenylation of Rab proteins which may be responsible for the other biological effects 
seen by statins [166]p. 
The aim of this work was to investigate the pleiotropic effects of statins, by performing mass 
spectrometry on the HUVEC polarised secretome after statin treatment.  
In order to gain accurate results from the mass spectrometry, it was necessary to ensure that 
the permeability of the ECs was not negatively affected by the statin treatment. If this was the 
case, and the ECs had leaky junctions I could not know whether proteins were truly secreted 
by the apical or basolateral membranes, as proteins may pass through the permeable layer. 
74 
 
Therefore, I performed permeability assays at various concentrations, as well as confocal 
imaging of VE-cadherin and ZO-1; two proteins involved in the formation of different cell-cell 
junctions. VE-cadherin is an endothelial specific adhesion molecule, and is a main component 
of adherens junctions [188]. ZO-1 is tight junction-associated protein, and the integrity of both 
these junctions are a marker for endothelial junction integrity [189]. This is important when 
studying the polarised secretome, to ensure secreted proteins cannot pass between cells to 
the opposite surface. 
The data from these studies allows a therapeutic plasma value of statin treatment to be 
selected, to perform mass spectrometry which has clinical significance. 
This research had three objectives: 
1) To investigate whether statins treatment affects the monolayer formation of HUVEC, 
by performing permeability assays using FITC-dextran, and immunofluorescence, to 
quantitatively measure the permeability of the HUVEC monolayer, and to visually 
assess the cell junctions respectively 
2) To use the data obtained from the first objective to choose the appropriate 
concentrations of statin to perform mass spectrometry of the HUVEC secreted 
proteome 
3) To analyse the secretome provided by mass spectrometry, and examine whether the 
secretion of any important proteins change after statin treatment 
With statins being one of the most commonly prescribed drug in the UK, further studies into 
the off-target effect of these drugs is of great importance to the health system and may indicate 

















4.2.1 Measurement of the effect of statins on endothelial permeability  
 
Two of the most commonly prescribed statins with the UK are atorvastatin, and simvastatin. 
The NICE guidelines recommend that 20 mg atorvastatin daily should be offered to people 
with a 10% or greater risk of developing CVD within the next 10 years [190]. In people who 
already have pre-existing CVD, for example a previous stroke or heart attack, 80 mg 
atorvastatin is recommended daily dose. Atorvastatin has a higher potency than simvastatin, 
with the cholesterol lowering effects of atorvastatin at a 10 mg dose, being equal to those 
observed in simvastatin at 40 mg dose [190]. At doses between 20-80 mg daily of atorvastatin, 
and 80 mg simvastatin are classed as ‘high-intensity’ statins, reducing more than 40% of 
cholesterol production.  
I started by researching the concentrations of atorvastatin and simvastatin used in previous 
biochemical studies of statin functions [191,192]. Based on these previous experiments, I used 
both atorvastatin and simvastatin dissolved in DMSO at 0.2 µM, 1 µM and 5 µM, along with a 
vehicle control of DMSO to ensure any effects on the cells were as a direct result of the statins. 
HUVEC were cultured at 1x105/mL onto Transwell inserts in EGM-2, before refreshing with 
HIFA media after 24 hours. This method of Transwell cell culture had been optimised by 
previously by my laboratory group, as it had been shown to support the formation of a confluent 
monolayer. At the same time as refreshing with HIFA media, statins were added, and then 
added again after 24 hours at the concentrations shown. By using the FITC-dextran 
permeability assay as described in 3.2.2, I could effectively measure the permeability of the 
monolayer. Figure 4.1A shows that the addition of simvastatin at these concentrations showed 
increasing permeability with increasing concentrations of statins. However, this increase in 
permeability was not found to be statistically significant. To investigate this further, HUVEC 
were cultured on coverslips, and the simvastatin was applied at the same concentration as 
before, before fixing and staining. Cells were also counterstained with DAPI, in order to 
visualise their nuclei. As the concentration of simvastatin increases (Figure 4.1B), the junctions 
appear to become weaker, however HUVEC are still shown to form junctions, even at 5 µM. 
At 0.2 µM, the junctions appear similar the control (Figure 4B), especially in the distribution of 
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ZO-1. However, at 1 µM and 5 µM the junctions appear to be thinner than compared to the 
control (4.1B). This supports the permeability data that simvastatin at these concentrations, 
whilst affecting the EC monolayer, did not significantly affect the EC monolayer. Thus, I can 



















0.2 μM 1 μM 5 μM Control 
Simvastatin 
concentration (μM) 
Figure 4.1. Addition of simvastatin has no significant effect on HUVEC cell:cell 
junctions. A) HUVEC were plated onto Transwell inserts, and simvastatin was added after 
24 hours, then again after 48 hours at the concentrations shown. FITC-dextran was added to 
the upper compartment, and fluoresce intensity was measured after 24 hours, by removing 
media from the lower compartment. No results showed statistical significance. Graphs are 
plotted as means ± SEM (n=5), and data is normalised to the control. Statistical analysis 
performed using a repeated measures one-way ANOVA and Dunnett’s multiple comparison 
post hoc test and P-values below 0.05 were considered to be statistically significant. B) 
HUVEC were grown on coverslips and treated after 24 hours and 48 hours with simvastatin, 
then fixed after a further 24 hours and stained for ZO-1 and VE-cadherin. ZO-1 and VE-
cadherin showed similar distributions at all concentrations. White arrows show similarity of 



























monolayer, and therefore forming a barrier preventing the diffusing of proteins between the 
medium. However, at increasing concentrations of simvastatin, I cannot be confident that the 
junctions are not affected. 
This experimental design was also followed for atorvastatin, with the same concentrations and 
controls being applied. However, as shown in Figure 4.2A it was found that at 5 µM the 
permeability of the monolayer, when measured by FITC-dextran absorbance increased 
significantly, with no significant effect at any of the other concentrations shown. This was a 
surprising result, as in the literature other studies have used atorvastatin at up to 50 µM and 
the cells have been shown to be viable [193]. To validate this, confocal microscopy of 
atorvastatin treatment at the same time points was used (Figure 4.2B). At concentrations 0.2 
µM and 1 µM, the distribution of ZO-1 and VE-cadherin suggest weaker junctions in 
comparison to the control, whilst at 5 µM HUVEC were shown to have completely retracted 
(Figure 4.2B), supporting the initial finding in the permeability assay. This was an unexpected 
result, as many previous studies, including by Zhang et al (2018) of atorvastatin on HUVEC 
have used concentrations much higher than 5 µM, and their cells were shown to be still viable 
at 50 µM treatment of atorvastatin [193]. However, the HUVEC in Zhang et al (2018) study 
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 10% heat-inactivated 
fetal bovine serum (FBS), whilst the HUVEC in this study were maintained in HIFA, which 
contains no serum. This is one factor that may account for the difference in cell viability, as 
the presence of serum in the media may have affected the effect that statins have upon 
HUVEC. The atorvastatin used in their experiment was obtained from Pfizer and the purity 
was not stated, whilst the atorvastatin in my study was obtained from Sigma-Aldrich and had 
a purity of 99.93%. It is not surprising however, that simvastatin did not show the same effect 
at 5 µM as simvastatin has a lower potency than atorvastatin, with 40 mg of simvastatin 
showing the same effect on HMG-CoA as 10 and 20 mg of atorvastatin [190].  
 
4.2.2 Optimisation of atorvastatin treatment for mass spectrometry  
 
The permeability experiments allow us to know the integrity of the monolayer, which is vital if 
wanting to investigate the secreted proteome. If the monolayer did not have good cell:cell 
junctions, and was ‘leaky,’ it would be impossible to determine whether a protein truly had 
been secreted by the basolateral surface, or whether it merely passed through the poorly 
formed junctions of the monolayer to enter the basolateral media. These concentrations were 
used as the literature showed their use in other previous experiments into atorvastatin on 

































Figure 4.2. Atorvastatin disrupts cell junctions at high concentrations. A) HUVEC 
were plated onto Transwell inserts, and atorvastatin was added after 24 hours, and again 
48 hours at the concentrations shown. FITC-dextran was added to the upper 
compartment, and fluoresce intensity was measured 24 hours after addition using media 
from the lower compartment. Atorvastatin at 5 μM had a significantly different permeability 
value to the control (P = 0.0147). Graphs are plotted as means ± SEM (n=5), and data is 
normalised to the control. Statistical analysis performed using a repeated measures one-
way ANOVA and Dunnett’s multiple comparison post hoc test and P-values below 0.05 
were considered to be statistically significant. B) HUVEC were grown on coverslips and 
treated after 24 hours and 48 hours with statins, then fixed after a further 24 hours and 
stained for ZO-1 and VE-cadherin. Cells were then imaged using confocal microscopy. 
The distribution of ZO-1 and VE-cadherin appears different at 1 μM compared to the 
control. At 5 μM treatment with atorvastatin, cells were unable to form junctions. White 
arrows shows where cell:cell junctions are not as tight at 1 µM atorvastatin compared to 
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no significant effect on the appearance of HUVEC. However, despite the regular use of high 
concentrations of statins employed in cell experiments, these concentrations of statins are not 
the plasma concentrations seen in a patient undertaking statin treatment [192,194]. At a 20 
mg dose of atorvastatin, the starting dose for the prevention  of cardiovascular events in a 
patient who has never previously experienced a cardiovascular event, the maximum plasma 
concentration is around 40 nM, with a mean of 15 nM.  [192]. 
To ensure these new concentrations (5 nM, 10 nM and 50 nM) also had no effect on the 
HUVEC monolayer, again permeability assays using simvastatin (Figure 4.3A) and 
atorvastatin (Figure 4.4A) were performed. None of these results were found to be significant 
when tested using ANOVA and Dunnett’s post hoc test. HUVEC grown on coverslips were 
also treated with statins at the same time and dosage as the Transwell inserts. Neither 
simvastatin (Figure 4.3A) nor atorvastatin (Figure 4.4B) had a noticeable effect on the cell 
junctions when stained for ZO-1 and VE-cadherin. Images were not obtained for 5 nM 
simvastatin or atorvastatin, however, due to the images of HUVEC at 10 nM and 50 nM 
showing no noticeable difference in characteristics in comparison to the control, it was 
assumed that 5 nM statin treatment would also cause no noticeable difference. 
As these initial experiments were involved in optimisation for further experiments in which the 
apical and basal media of the Transwell would be used, it was important to also investigate 
whether the integrity of the monolayer was also maintained on Transwell. This is important 
because the coverslips used in the imaging were made of glass and coated in fibronectin at 1 
ng/mL, whilst Transwell inserts are 10 µM thick polyester membranes with 0.4 µm pores and 
are coated in a triple coat of fibronectin, gelatin and collagen. This could mean the images of 
the HUVEC grown on the coverslips may not be accurate for generalising to culture on 
Transwell. However, as shown in Figure 4.5, there is no noticeable difference between the 
ZO-1 and VE-cadherin on Transwell and the ZO-1 and VE-cadherin in HUVEC cultured on 
glass coverslips. One contrast between the images however is that in the Transwell images 
(Figure 4.5), DAPI staining appears to be very common and not focussed in the nuclei, as 
would be expected and is seen in the other Figures (4.1,4.2,4.3,4.4). This is a well-known 
issue with staining Transwell inserts, and pores are often visible in microscope images. 
Transwell inserts may possibly provide a superior image to that of glass coverslips, as the 
permeable membrane allows the basolateral side of the cells to also permeabilise when 








Figure 4.3. Low concentrations of simvastatin have no significant effect on HUVEC 
cell:cell junctions. A) HUVEC were plated onto Transwell inserts, and simvastatin was 
added after 24 hours, then again after 48 at the concentrations shown. FITC-dextran was 
added to the upper compartment, and fluorescence intensity was measured after 24 hours 
using media from the lower compartment. Graphs are plotted as means ± SEM (n=5), and 
data is normalised to the control. Statistical analysis performed using a repeated measures 
one-way ANOVA and Dunnett’s multiple comparison post hoc test and P-values below 
0.05 were considered to be statistically significant. B) HUVEC were grown on coverslips 
and treated after 24 hours and 48 hours with simvastatin, then fixed after a further 24 hours 
and stained for ZO-1 and VE-cadherin. Cells were then imaged using confocal microscopy. 
No concentration of simvastatin showed an obvious effect on the junctions. White arrows 
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Figure 4.4. Low concentrations of atorvastatin have no significant effect on HUVEC 
cell:cell junctions. A) HUVEC were plated onto Transwell inserts, and atorvastatin was 
added after 24 hours, then again after 48 hours at the concentrations shown. FITC-dextran 
was added to the upper compartment, and fluorescence intensity was measured after 24 
hours of media of the lower compartment. Graphs are plotted as means ± SEM (n=5), and 
data is normalised to the control. Statistical analysis performed using a repeated measures 
one-way ANOVA and Dunnett’s multiple comparison post hoc test and P-values below 
0.05 were considered to be statistically significant. B) HUVEC were grown on coverslips 
and treated after 24 hours and 48 hours with atorvastatin, then fixed after a further 24 
hours and stained for ZO-1 and VE-cadherin. Cells were then imaged using confocal 
microscopy.  No concentration of atorvastatin showed an obvious effect on the junctions.  




















Figure 4.5. Atorvastatin has no significant effect on HUVEC cell:cell junctions 
when grown on Transwell. HUVEC were plated onto Transwell inserts, and 
atorvastatin was added after 24 hours, then again after 48 hours at the concentrations 
shown. Inserts were fixed using PFA and stained for ZO-1. Cells were then imaged 
using confocal microscopy. Like when grown on the coverslips, atorvastatin showed no 
effect on the ZO-1 distribution. DAPI nuclear staining also stains the pores on the 
Transwell insert. White arrows show similarities between ZO-1 distributions in images. 
Scale bar = 10 μm. 
84 
 
4.2.3 Atorvastatin treatment generally causes an increase of the apical/basolateral secretion 
ratio compared to the control 
 
Performing the permeability experiments allowed optimisation of the experimental design for 
TMT mass spectrometry. The measurement of the effect at the higher concentrations of the 
permeability of HUVEC allowed understanding of the toxicity of statins on HUVEC and 
followed the other literature. However, for the results to be clinically relevant, the lower 
concentrations were used. Initially in the permeability experiments at the lower concentrations, 
5 nM, 10 nM and 50 nM were used. However, with the difference of 5 nM and 10 nM being 
only two-fold, and the difference of 10 nM and 50 nM being five-fold, 15 nM replaced 10 nM, 
allowing for a three-fold difference between 5 nM and 15 nM, and almost a three-fold 
difference between 15 nM and 50 nM. 15 nM was not investigated for its effect on permeability 
but was considered suitable as a range of concentrations above and below 15 nM had shown 
no effect on the permeability.  
During the preparations of samples for mass spectrometry, one of the ultracentrifuge tubes 
cracked, losing the 5 nM basolateral sample. Instead, a sample collected from a previous 
experiment was used. This previous experiment however, had used polycarbonate Transwell 
inserts as compared to permeability experiments that had used polyester (PET) inserts. As it 
is harder to see the cells monolayer upon a polycarbonate membrane as they are translucent, 
when taking the sample there was no idea about the integrity of the monolayer. However, a 
few permeability assays had previously been performed on polycarbonate Transwell inserts, 
and there had been no considerable difference in fluorescence absorbance in FITC-dextran 
compared to when the polyester Transwell inserts were used in other experiments, suggesting 
it was suitable as a replacement.  
However, when the results from the mass spectrometry were returned, the result for 5 nM 
basolateral total abundance looked abnormal (Figure 4.6) when compared to the apical and 
basolateral samples of the control, 15 nM and 50 nM. Although the apical total abundance at 
5 nM was comparable to the other three concentrations, the fact the 5 nM value was so 
obscure, and had come from a previous experiment with a different insert material that the 5 
nM result was not used in any further analysis. To further support this decision, total 
abundance graphs and the corresponding R2 value of the control vs 5 nM, 15 nM and 50 nM 
were created (Figure 4.7). R2 values are statistical measurements that correspond to how 
much variation in the experimental (in this case the concentration of atorvastatin treatment) is 
due to the control data, and how well the data fits a regression line. The data was transformed 




Figure 4.6. The total protein abundance was higher at 5 nM basolateral than any 
other condition. During the mass spectrometry preparation, the 5 nM atorvastatin sample 
was lost, and a replacement was used from a previous experiment. To investigate whether 
this sample was suitable to use in the analysis, the sum of the total abundance of the three 
different concentrations compared to the control was analysed. Generally, all apical and 
basolateral abundances were about equal, with the largest difference of samples of the 
same experiment (between 50 nM apical and control apical) being 1.5-fold, whilst the 
smallest difference between 5 nM basolateral and any other basolateral sample was at 
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better visualise the differences between values. The values for 15 nM and 50 nM against the 
control gave very high R2 values, both above 0.9 suggesting very high positive correlations 
between the variables, whilst for 5 nM, the R2 value was 0.5178, suggesting a moderate 
correlation, and has high residuals (the distance between the regression line and the observed 
value). Whilst it is unknown whether the 5 nM sample was a true reflection of the clinical use 
of statins ECs, the substantial increase in abundance of the 5 nM sample, the moderate R2 
value and the high residuals compared to 15 nM and 50 nM meant there was considerable 
evidence for excluding 5 nM from the rest of the analysis.  
In order to analyse the data further, all non-human proteins, such as bovine and contaminants 
such as keratin were removed from the data set, as defined in the mass spectrometry data, 
with 271 proteins remaining. Proteins which had missing abundances in any of the columns 
were also removed, as otherwise the data would be unable to be compared at different 
concentrations. The data was further processed by creating ratios of the apical/basolateral 
secretion of each protein, and plotted as values normalised to the control, and again, log2 
values were used (Figure 4.8). Figure 4.8 shows that generally, the apical/basolateral ratio of 
the protein increased with increasing concentrations of atorvastatin. Highlighted in figure 4.8 
are four proteins which show the highest effect on the ratio: collagen α1, a secreted protein 
that is the major component of type I collagen, which is found in most connective tissue; 
Chaperone containing TCP1, a molecular chaperone complex that assists protein folding 
normally present within the cytoplasm; Inter-α-trypsin inhibitor, a secreted protease inhibitor 
that is involved in the inflammatory response; and serine-tRNA ligase, a cytoplasmic enzyme 
that is involved in the metabolism of glycine, serine and threonine and aminoacyl-tRNA 
biosynthesis. Whilst this mass spectrometry purely looks at the secretome, sometimes cellular 
components can enter the media due to cell lysis before extraction of media, or cells not being 
removed during mass spectrometry sample preparation, which accounts for proteins such as 
Chaperone containing TCP1 and serine-tRNA ligase. However, these cytoplasmic proteins 
are of little interest, as they will only come from a few cells and therefore their abundance and 
ratios cannot be taken as reliable.  
Using UniProt, the proteins were organised into whether they were known secreted proteins 
or not, and the proteins which were not secreted were ignored, reducing the data for 62 
proteins (Figure 4.9). Again, generally the apical/basolateral secretion of proteins increased 
with atorvastatin treatment compared to the control, whilst a few proteins decreased.   
Figure 4.10 shows the functions of the 52 known secreted proteins found in the HUVEC 
atorvastatin secretome using TMT mass spectrometry. Almost 30% of these proteins are 
proteins with are associated with the ECM, which, as one of the major secreted components 
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Figure 4.7. Total protein abundance at 5 nM atorvastatin is considerably different to any 
other protein abundance. During the mass spectrometry preparation, the 5 nM atorvastatin 
basal sample was lost, and a replacement was used from a previous experiment. To see 
whether this sample was suitable to use in the analysis, total abundance graphs of the 
treatment compared to the control was performed. A) The control apical and basal abundances 
were added together, and the log2 values plotted against the log2 value of apical and basal 
abundance at 5 nM. The graph has an R
2
-value of 0.5178, suggesting there is a not a strong 
positive correlation between the 5 nM atorvastatin treatment and the control. B) The control 
apical and basal abundances were added together, and the log2 values plotted against the 
log2 value of apical and basal abundance at 15 nM and had an R
2
-value of 0.9551, suggesting 
a strong positive correlation between the control and 15 nM total abundance. C) The control 
apical and basal abundances were added together, and the log2 values plotted against the 
log2 value of apical and basal abundances at 5 nM had an R
2
-value of 0.9558, suggesting a 
strong positive correlation between the control and 50 nM total abundance. D) Apical, basal 
and total abundance values for each condition was plotted, showing the basolateral sample at 
5 nM was considerably higher than any other condition, and as was the corresponding total 
protein abundance at 5 nM.  
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Apical/Basal ratio compared to control
0 nM 15 nM 50 nM
Figure 4.8. The apical/basolateral secreted ratio of 15 nM and 50 nM atorvastatin total mass spectrometry proteins differs to control 
ratio. The apical/basolateral ratios of 271 proteins for each condition were collated and the log2 values were plotted. Generally, atorvastatin 
treatment increases the apical/basolateral secreted ratio of the protein, whilst the apical/basolateral ratio of few proteins’ decreases. All non-
human proteins and contaminants were removed, as were proteins where one or more abundance values were absent. All data is n=1. 
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Ratio of secreted proteins compared to control
0 nM 15 nM 50 nM
Figure 4.9. The apical/basal ratio of known secreted proteins generally increases 
with atorvastatin treatment compared to the control. The proteins shown in Figure 15. 
were analysed on whether they are a known secreted protein or not, and 52 proteins were 
found to be of this category. The log2 ratios of these proteins were plotted, and generally 
the apical/basal ratio increased in comparison to the control, with many proteins found to 
become more apical, causing the ratio to increase. Proteins highlighted are analysed futher 
in this thesis. All data is n=1. 
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of ECs are to be expected and shows the high range of genes that interact to form a stable 
ECM. Other popular proteins include enzymes, such as matrix metalloproteinase inhibitor 
TIMP1, which have a role in remodelling the ECM by controlling the activity of matrix 
metalloproteinases [195]. Growth factors, and proteins that bind growth factors are also 
secreted by ECs, including placental growth factor PGF, a member of the vascular endothelial 
growth family (VEGF) and associated with angiogenesis (Figure 4.10). Raised levels of PGF 
is implicated in chronic inflammatory disease, however, as the cells used in this experiment 
are HUVEC, it is highly likely these levels are just due to the cell type as these cells obviously 
play a large part in placental growth [196]. Another function of the secreted proteins is their 
role in haemostasis, controlling of the blood clotting pathways. One protein, vWF is an 
important protein in blood clotting, and deficiencies in this protein leads to the pathological 
condition vWF disease, symptoms of which include high risk of bleeding, and high levels are 
associated with thrombosis risk  [39]. Other proteins include growth factors, immunity, and 
other secreted proteins include TCN2, a secreted transport protein. 
However, in many of the proteins the secretion changed only slightly, and as shown in Figure 
4.9, many of the protein’s ratios are within 0 and 1 on the log2 scale, so their secretion was 
not substantially affected by the addition of atorvastatin.  
 
4.2.4 Treatment with atorvastatin  
 
Whilst the smaller list of proteins from the secretome obtained so far had been reduced to 59, 
many of these proteins’ values fluctuated around 0-1 on the log scale, so did not show a 
substantial difference in their secretion. Also, other proteins showed that the 15 nM 
concentration caused a higher increase in secretion that the 50 nM concentration, and without 
a 5 nM sample any relationship cannot be strongly distinguished. Having only performed one 
experiment with no repeats, I cannot be sure whether it is correct to disregard these data 
points, or whether they are important. However, it would be unfeasible to repeat the mass 
spectrometry due to time constraints. 
To evaluate the results, proteins were studied to see whether they had a log2 effect value of 
above or below 0.9 and -0.9 respectively, giving a final amount of 11 proteins which had 
successfully fulfilled all the criteria.  
The proteins showed a range of effects with the addition of atorvastatin. In some proteins, the 
overall secretion of the protein increases with atorvastatin treatment, with both their apical and 



















FBN1, FN1, LGALS1, 
HSPG2, LAMA4, 
LAMB1, LAMC1, 
NID1, PRG1, THBS1 
Other secreted 
enzymes 
TIMP1, TIMP2, FASN, 
MMP1, GLO1, LOXL2, 






























Figure 4.10. Function of proteins in the HUVEC atorvastatin secretome. HUVEC 
secretome was analysed using TMT mass spectrometry, then analysed for protein function 
using UniProt (www.uniprot.org) 
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and in others the basal secretion increased, with no effect on the overall secretion, suggesting 
atorvastatin changed the polarity of the protein secretion (Figure 4.12,4.15). However, in some 
proteins (Figure 4.14) the addition of atorvastatin showed a substantial change in the secretion 
of the protein. 
Figure 4.11 shows proteins where the total secretion of the protein increases with atorvastatin 
treatment. The first protein shown is thrombospondin 1 (TSP1). TSP1 is an adhesive 
glycoprotein, that can bind to other proteins, including fibrinogen, laminin and collagen [197]. 
TSP1 levels have also been shown to affect angiogenesis, being antiangiogenic at high 
expression, and antiangiogenic at low expression [197]. When atorvastatin is added to 
HUVEC, the apical secretion of the TSP1 increases, whilst the basal secretion remains almost 
constant (Figure 4.11A). Despite this slight fall in basal secretion, the overall TSP1 abundance 
increases by about 1.25-fold between 0 nM and 15 nM, however, only increases slightly at 
addition of 50 nM. Studies by Keenan et al (2006), suggested that the addition of fluvastatin 
decreased levels of TSP1 [198]. However, they used much higher levels of statins that than 
used within this study, at 0.25 µM and 1 µM, so whilst the reduction in TSP1 may occur at 
these concentrations, at lower concentrations, such as the ones used with my study may have 
different effects.  Another study by Zagorska et al (2006) also showed that at 1 µM atorvastatin 
treatment, expression of TSP1 also decreased, however, they did not show the effect at 10 
nM. High levels of TSP1 are associated with decreased angiogenesis, and levels of TSP1 are 
found in increase after vascular injury [199]. TSP1 has also been shown to activate 
transforming growth factor (TGF-β), an anti-inflammatory factor, and it is suggested that 
activating TSP1 may be of therapeutic value in treatment of cardiovascular disease [199]. 
However, due to these conflicting findings in studies of TSP1 and its effect in disease, as well 
as the variety of concentrations atorvastatin used, my results do not show any clear indication 
of whether this increase of TSP1 has a positive or negative effect of statins.  
Other proteins which follow this same pattern are ECM glycoproteins, laminin subunit γ-1, 
which is present in all basement membranes. The addition of atorvastatin causes an increase 
in the apical secretion of laminin (Figure 4.11C), and an increase in the overall secretion of 
atorvastatin (Figure 4.11D). At 15 nM, both the apical and basolateral secretion abundance 
increases steeply compared to the control, however at 50 nM the basal secretion falls back to 
a similar level as the control (Figure 4.11C). Overall, the total abundance of laminin subunit γ-
1 increases with addition of atorvastatin, peaking at 15 nM (Figure 4.11D) However, secretion 
at 50 nM is still considerably more than the control secretion (Figure 4.11D). 
Biglycan is a member of the small proteoglycan family, macromolecules of the ECM. Recently, 
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Figure 4.11 Total secretion of certain proteins increases with atorvastatin treatment. 
Change in the abundance of proteins in response to various concentrations of atorvastatin. 
(A, C) show the separate apical and basal abundance, and (B,D) show the pooled data of 





in depositions of collagens and mediation of cytokines and growth factors, amongst others. 
Previous studies have found that increased levels of vascular biglycan correlate with increased 
atherosclerosis in mice, and that accumulation of biglycan may contribute to the early stages 
of atherosclerosis [200,201]. This is due to biglycan being the most co-localised proteoglycan 
with apolipoprotein B which causes retention of low density lipoproteins (LDL), the ‘bad’ 
cholesterol, in the vessel wall, and vessels with increased biglycan have increased lipid 
retention [200]. Lipid retention is a contributing factor the initial stages of atherosclerosis. 
Increased levels of biglycan have also been associated with other contributing factors to 
atherosclerosis, including inflammation and regulation of growth factor availability, but also 
increased levels shows protection against hypoxia [200,202]. Whilst other studies have 
suggested that biglycan contributes to atherosclerosis, a study by Csont et al (2010), found 
that biglycan leads to protection against hypoxia/reoxygenation injury, by inducing 
cardioprotective genes such as NO synthases in the heart. This study found that it was the 
polarisation of biglycan secretion that changed, with the basolateral secretion of biglycan being 
almost 5-fold higher than the apical secretion at 0 nM (Figure 4.12A). At addition of 15 nM 
atorvastatin, both the apical and basal levels of secretion of biglycan rose, with the increase 
of apical secretion more substantial than the increase of the basal secretion (Figure 4.12A). 
However, my study showed at 50 nM atorvastatin, the basal levels of the protein secretion 
decreased, whilst the apical levels increase slightly compared to 15 nM (Figure 4.12A). I found 
that overall abundance of biglycan remains steady between the control and 50 nM, the total 
abundance peaks at 15 nM (Figure 4.12B). Overall, this study found that the apical secretion 
of biglycan increased, whilst the basolateral decreased, so further investigation is needed to 
examine whether it in increased secretion of biglycan from the apical surface is the significant 
factor in these effects shown. 
Another protein indicated to be significant by my study was insulin-like growth factor-binding 
protein 7 (IGFBP7), which acts as a carrier protein for insulin-like growth factor (IGF-1) and 
insulin. IGFBP7 regulates cellular functions such as proliferation and adhesion, and has been 
proposed to regulate angiogenesis  [203]. IGFBP7 is also a structural constituent of the ECM, 
as was biglycan, amongst others, suggesting that the basolateral secretion of these 
components is affected by atorvastatin addition. In Figure 4.12C, it shows that initially, the 
basolateral secretion of IGFBP7 is about three times more than the apical secretion. However, 
with the addition of 15 nM atorvastatin, this ratio changes, and the secretion of IGFBP7 from 
the basolateral surface becomes only twice the secretion from the apical surface (Figure 
4.12C) as the apical secretion increases. At 50 nM atorvastatin, the apical secretion has 
remained similar to the secretion at 15 nM atorvastatin and the basolateral secretion fallen 
slightly, meaning the basal secretion is less than twice of the apical secretion (Figure 4.12C).  
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Figure 4.12 Apical secretion of certain proteins noticeably increases, whilst basal 
level decreases slightly with atorvastatin treatment. Change in the abundance of 
proteins in response to various concentrations of atorvastatin. (A,C,E) show the separate 



























IGFBP7 is a marker of cell cycle arrest, and often shows increased levels in ischemic 
conditions, and is often used a marker for diagnosis of acute kidney injury [204]. IGFBP7 has 
also been shown to be a component of Weibel-Palade bodies, storage granules that contain 
von Willebrand factor (VWF), by binding to large vWF strings when they are released by ECs 
[205]. As VWF is a carrier for FVIII, which is involved in blood clotting, the increase in IGFBP7 
secretion from the apical surface could allow for the rapid release of Weibel-Palade bodies 
from the apical surface, which may be crucial in maintaining vascular homeostasis [205]. The 
change in polarisation of IGFBP7 is not due to overall increased abundance (Figure 4.12D), 
as the total amount of IGFBP7 remains steady between 0 nM and 50 nM, however increases 
slightly between 0 nM and 15 nM, before decreasing back to the level at 0 nM at 50 nM 
atorvastatin. As Weibel-Palade body release is associated with thrombosis, the secretion of 
these may increase in atorvastatin treatment, which may increase the risk of thrombosis [150]. 
Whilst this may initially be positive as it could improve initial damage to the vessel by plugging 
damage with a clot, increased secretion may cause unwanted thrombosis and increased 
plaque formation [206]. 
Perlecan shows a similar pattern to that of biglycan and IGFBP7, where the apical secretion 
noticeably increases with increasing concentrations of atorvastatin, whilst the basal 
concentration slightly decreases (Figure 4.12). Perlecan, like biglycan is a component of the 
ECM and regulates many cellular processes, including cell adhesion, thrombosis and lipid 
metabolism [173]. Generally, perlecan is secreted basally into the underlying ECM and my 
data supports this (Figure 4.12E), which shows at 0 nM atorvastatin, the basal secretion is 
about seven-fold more than the apical secretion. This remains similar at 15 nM atorvastatin; 
however the basal secretion falls to less than 4.5-fold that of the apical (Figure 4.12E), and by 
50 nM atorvastatin the basal secretion is only about 3.5-fold more than the apical (Figure 
4.12E). This suggests that the addition of atorvastatin changes the polarisation of perlecan 
secretion as shown in Figure 4.12F, the overall abundance is similar at 0 nM and 50 nM, 
however, the abundance increases at 15 nM. This is a similar pattern also seen in both 
biglycan and IGFBP7 secretion, suggesting either the statins had a most considerable effect 
at 15 nM, or there was a difference in the initial loading of the samples for mass spectrometry. 
A study by Vikramadithyan et al (2004), found that in atherosclerosis that perlecan deficiency 
leads to less atherosclerosis [207].  However, whilst they found that loss of perlecan lead to 
less atherosclerosis in early lesions, in more advanced lesions, perlecan was found in the core 
regions of the atherosclerotic plaque, and perlecan was found to be a major component of 
more advanced plaques [207]. They also showed that decreased perlecan caused a dramatic 
and significant reduction in lesion in size in male mice, however, this result was not significant 
in female mice suggesting that, as men are more pre-disposed to cardiovascular disease than 
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women, perlecan secretion may play a part in this genetic difference [207,208]. Perlecan, 
along with other proteoglycans, is also associated with lipid retention in the subendothelial 
layer, which is a marker for early atherosclerosis [209]. One study found mice with 
proteoglycan binding defection LDL, developed significantly less atherosclerosis than wild-
type LDL, suggesting that the subendothelial region, which contains perlecan, and the 
retention of lipids is an early step in atherogenesis [209]. This suggests that the decreased 
level of basal secretion of perlecan that treatment with atorvastatin showed could initially 
decrease the risk of atherosclerosis by reducing lipid retention, however, in more developed 
plaques, the increase apical secretion could contribute to plaques, as perlecan was found at 
the core of the atherosclerotic lesions.  
Collagen-α1 is a component of the ECM, which is secreted by ECs. ECM deposition is an 
important contributor to the cardiac remodelling which is seen following myocardial injury, such 
as in myocardial infarction [210]. When atorvastatin is added to HUVEC, the basal secretion 
collagen is initially almost 10-fold that of the apical secretion. The addition of 15 nM 
atorvastatin reduces the basal secretion to less than 1.5-fold that of the apical secretion, and 
50 nM is less than 1.25-fold (Figure 4.13A). The overall secretion of collagen decreases with 
increasing concentrations of atorvastatin (4.13B). A study by Martin et al (2005) found that 
atorvastatin appeared to directly inhibit the production of collagen by cardiac fibroblasts in a 
dose-dependent manner [210]. The data from this study suggested that statins could show 
mechanistic support for use in patients with heart failure. My data of the secretion of collagen 
supports their data, as it also showed a decrease in the overall secretion of collagen in a dose-
dependent manner (Figure 13B). However, my data expands on the finding of Martin et al 
(2005), as it clearly shows the difference in both apical and basal secretion of collagen 
depending on dose, as well as the overall secretion. This is important as it shows whilst the 
basal secretion of collagen-α1 decreases, the apical levels increases, although the overall 
level decreases. Normally, the secretion of collagen is strongly polarised to the basolateral 
surface of the cell, but as the dose of atorvastatin increases, the basal secretion decreases. 
This could suggest that although atorvastatin decreases the overall secretion of collagen α1, 
the apical secretion of collagen could in fact increase, and the effects of this would have to be 
investigated further. 
Another group of proteins showed that with atorvastatin treatment, the apical secretion of 
these proteins noticeably increased, whilst the basal secretion of these proteins noticeably 
decreased (Figure 4.14). One protein, latent-transforming growth factor β-binding protein 2 
(LTBP2) was initially secreted twice as much basally than apically (Figure 4.14A), however, 
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Figure 4.13 Apical secretion of collagen-α1 increases with atorvastatin treatment, 
whilst basal secretion decreases. Change in the abundance of collagen-α1 in response 
to various concentrations of atorvastatin. A) The separate apical and basal abundance B) 
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Figure 4.14 Apical secretion of certain proteins increases, whilst basal level decreases with 
atorvastatin treatment. Change in the abundance of proteins in response to various 
concentrations of atorvastatin. (A,C,E,G) show the separate apical and basal abundance, and 






















































































than the basal secretion (Figure 4.14A). Unlike other members of the LTBP family, it is 
transforming growth factor-β independent. LTBP2 is also an ECM protein and interacts with 
fibrillin in the ECM, and is expressed abundantly in elastic tissues [211]. Studies have 
suggested that LTBP2 plays a role in the development of the extracellular fibrils, and may be 
involved in protecting these fibrils from enzyme degradation, rather than the formation of these 
fibrils [212].  Studies have also shown that LTBP2 could be an antiadhesive matrix component, 
and increased secretion from the apical surface could be angiogenic, which other studies have 
previously reported statins to be [213,214]. Like the other secreted proteins, the overall 
abundance of LTBP2 does not show a noticeable difference at any concentration (Figure 
4.14B), suggesting that it is the change in polarised secretion of LTBP2 that could show these 
effects. 
Twisted gastriculation protein homolog 1 (TWSG1) is a known antagonist of bone 
morphogenic protein 2 (BMP-2) activity [215]. BMPs are secreted by macrophages and are 
important regulators in blood vessel and vascular disease, and module vascular calcification 
[215–217]. BMPs are also involved in inflammation and have been shown to stabilise 
atherosclerotic plaques, by inducing vascular calcification [217]. In this study, at 0 nM the 
basal secretion of TWSG1 is twice as high as the apical secretion, however at 15 nM the apical 
secretion increases to higher than that of the basal secretion (Figure 4.14C). At 50 nM, the 
apical/basolateral secretion is equal (Figure 4.14C). BMP-2 secretion is downregulated in 
statin treatment, which suggests that statins affect proteins that are involved in the modulation 
of BMP [218]. However, TWSG1 is an antagonist of BMP, and my study shows that the total 
abundance of TWSG1 is only slightly upregulated at 15 nM atorvastatin, and decreases to 
below the 0 nM level at 50 nM (Figure 4.14D), it suggests that other proteins involved in the 
modulation of BMP-2 are involved. Causes of atherosclerosis, such as oxidised low-density 
lipoproteins induce the expression of BMP-2s, suggesting BMP2 is important in the 
development of atherosclerosis [217]. As my study found the overall secretion of TWSG1 did 
not markedly change with atorvastatin treatment, and the study by Zhang et al (2008) used 
higher concentrations of atorvastatin (1-10 µM), further investigations are needed to see 
whether this effect also occurs at lower concentrations, and whether this can give insight into 
other roles of statins on ECs [218].  
Inter-α trypsin inhibitors (IαI) are plasma proteins that function as protease inhibitors. IαI forms 
complexes with hyaluronan, a component of the ECM to create serum-derived hyaluronan 
associated protein (SHAP)-HA complexes [219]. These complexes are found to be increasing 
in inflammatory conditions, including rheumatoid arthritis and Crohn’s disease [219]. My study 
found that initially, the apical secretion of IαI is very low, however this increases at 15 nM, and 
increases again at 50 nM (Figure 4.14E). The basal secretion, however, decreases with 
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addition of atorvastatin (Figure 4.14F). There are very few studies into IαI, however, some 
studies have suggested it interacts with hyaluronan, which forms part of the ECM [219]. My 
study does not show the overall abundance of IαI confidently increasing or decreasing, so 
previous studies into IαI cannot be generalised to the effects on statins. However, as this 
protein plays a role in inflammation, and interacts with proteins within the ECM, it is reasonable 
to assume that statins would influence the polarised secretion of this protein [219]. 
Nonetheless, again, further investigations are needed into this protein. 
Protein-glutamine gamma-glutamyl transferase 2 (TGM2), is also known as tissue 
glutaminase, a calcium dependent enzyme that crosslinks proteins between the amino lysine 
group and the carboxamide of glutamine. As an extracellular protein, TGM2 binds protein in 
the ECM, especially fibronectin, and plays roles in cell adhesion and wound healing [220]. My 
study shows that initially, the apical secretion of TGM2 was twice the amount of the basal 
secretion (Figure 4.14G), which is unlike many of the other proteins where the opposite 
occurred.  With increasing concentrations of atorvastatin, the basal secretion of TGM2 
decreased, however the apical secretion increased (Figure 4.14G), until it was over 10-fold 
higher than the basal secretion at 50 nM. Overall, the total abundance of atorvastatin 
increases with increasing concentrations of atorvastatin, however, at 15 nM atorvastatin the 
total abundance decreases slightly (Figure 4.14H). A previous study on the effect of TGM2 
secretion on HUVEC treated with atorvastatin also found that atorvastatin treatment increased 
the expression of TGM2 [221]. This study showed that by cross-linking the ECM, TGM2 was 
able to indirectly stabilise the basement membrane, which could promote integrity of the vessel 
wall, providing previously unknown information about the pleiotropic effects of statins [221]. 
The study by Soehnlein et al (2004), used higher concentrations (1-10 µM) than my study, 
suggesting that the increase in TGM2 expression could occur at lower concentrations of 
atorvastatin than they used [221]. However, the effects of increased TGM2 showing stabilising 
effects mainly occurred in the ECM, by cross linking ECM components including fibronectin, 
whilst my study showed that the basal secretion of TGM2 decreased with increasing 
concentrations of atorvastatin. Whilst my study provides further evidence that atorvastatin 
does increase TGM2 expression, further studies are needed to investigate the stabilising 
effects of atorvastatin at the lower concentrations I used, and the significance of the changed 
polarisation. Studies also found that increased expression of TGM2 stabilised atherosclerotic 
plaques, decreasing their chance of rupture [221,222]. This suggests one of the positive 
effect’s statins may have, endothelial stability. 
Macrophage migration inhibitory factor (MIF) shows an increase in total abundance with 
increasing atorvastatin treatment (Figure 4.15B). Unlike the other proteins, the apical secretion  
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Figure 4.15 Apical secretion of macrophage migration inhibitory factor remains 
steady, whilst basal secretion noticeably changes with atorvastatin treatment. 
Change in the abundance of proteins in response to various concentrations of atorvastatin. 
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is higher than the basal at 0 nM (Figure 4.15A), and the apical secretion remains steady at 
increasing concentrations of atorvastatin (Figure 4.15A). However, unlike the other proteins 
which had their secretion changed by atorvastatin, the basal secretion of MIF increases with 
increasing concentrations of atorvastatin (Figure 4.15A). The role of MIF within the body is to 
prevent the macrophage migration out of capillaries. During times of stress, and pro-
inflammatory mediators, MIF is rapidly released from ECs [223]. MIF is a key cytokine in 
inflammatory immune diseases, such as rheumatoid arthritis MIF has also been linked to the 
formation of atherosclerosis, and MIF has been shown to be functionally linked to 
atherosclerotic plaques in vivo [224]. Whilst this provides no suggestion of why the protein is 
upregulated with increasing additions of atorvastatin, MIF has been shown to stimulate the 
production of quiescent mouse fibroblasts, which are critical for wound healing, where it is 
rapidly released [225]. However, again the role in wound healing is uncertain, and needs to 
be ascertained by further research. However, as the increase in basal secretion is only two-
fold (Figure 4.15A), the significance of these is unknown. 
My results show that atorvastatin changes the polarised secretion of a subset of proteins. My 
optimisation for mass spectrometry involving the permeability experiments and images 
suggest that this is not due to leakage of the protein across the cell monolayer, but instead 
the addition of atorvastatin causes an internal change in the protein’s delivery to the particular 
surface membrane. Previous studies have suggested that the addition of statins improve 
endothelial integrity, and that statins could be protective against atherosclerosis, in ways other 
than reduce cholesterol levels [226]. However, due to the current lack of studies into polarised 
secretion of ECs, further investigation is needed into these proteins, and whether their change 














The importance of statins as a prescribed drug cannot be understated, with roughly 6 million 
people taking them each day. However, whilst the cholesterol lowering effects of statins are 
well known, there is limited understanding about the off-target effects. One of the main 
indications for statins is atherosclerosis, where the arteries become hardened and narrow, 
which can lead to myocardial infarction. As ECs line these vessels, any pleiotropic effects on 
the polarised secretion of ECs could be clinically relevant. 
After finding the statins did not significantly affect the integrity of the EC monolayer, I was able 
to examine the polarised secretome of statin treated HUVEC. Using mass spectrometry, I 
compared the apical/basolateral secretion of HUVEC at 0 nM, 15 nM and 50 nM atorvastatin 
treatment. These results allowed me to investigate whether atorvastatin affected polarised 
secretion, and whether there was a relationship between the dose and how much the secretion 
was affected. Whilst much of the data in this chapter was at least n=3, the data obtained in 
my mass spectrometry was n=1, due to time limitations. Therefore, no clear conclusion or 
importance can be drawn from the analysis of this dataset. The proteins selected for analysis 
may not show any difference in secretion in another mass spectrometry experiment, and other 
proteins discarded may be of importance. If I did have time to make my data n=3, I would look 
at the proteins which the secretion changed consistently in all of the experiments, reducing 
variability and improving validity of my results. 
In my analysis I also removed proteins with 0 abundance, in any of the conditions. As I had 
already had to disregard my results from the 5 nM sample, having a 0 value in any of the other 
samples would further reduce my ability to see any patterns within my results. It is debatable 
of whether this was the correct decision to make, as one of these proteins may have been so 
significantly affected by the addition of statins that the amount secreted dropped to 0. 
However, due to this being a preliminary study, it would not have been feasible to include any 
0 values. 
My results showed that atorvastatin mainly increased the apical/basolateral secretion of a 
subset of proteins, particularly of proteins involved in the ECM, such as biglycan and TSP1. I 
then analysed this subset further to find proteins with a relationship between the 
apical/basolateral ratio of protein secretion, and the increasing dose of atorvastatin treatment.  
My research showed that atorvastatin increased the apical/basal polarised secretion of 
proteins including biglycan and perlecan, which have both been previously shown to increase 
the risk of atherosclerosis [200,207]. However, my research also showed that atorvastatin 
treatment increased the apical/basal secretion ratio of TGM2, as well as increasing the overall 
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secretion. Previous studies have shown that the increased secretion of TGM2 stabilises 
atherosclerotic plaques, decreasing their chance of rupture [221,222]. The rupture of 
atherosclerotic plaques often results in occurrence of a myocardial infarction, which can be 
fatal [169]. Other proteins affected by the addition of statins are TWSG1, an antagonist of the 
cytokine BMP-2 and the cytokine MIF. Increased secretion of BMP-2 and MIF is thought to be 
implicated in the progression of atherosclerotic plaques. However, the increased secretion of 
TWSG1 may decrease the secretion of BMP-2 therefore decreasing the risk of atherosclerosis 
[217]. 
The data from my study suggests that the addition of statins can have both a positive and 
negative effect on the formation, progression, and prognosis of atherosclerosis. However, 
there is limited understanding of the secretion of ECs, and even less into the polarised 
secretion. Further research is required to investigate the secretome of ECs, in order to really 
understand the implications of the altered secretion that occurs within the formation of 
atherosclerotic plaques. This research would allow us to understand the effect of statins upon 
the secretion of ECs in atherosclerosis, and the contribution to the disease progression. 
Further research could provide information about other therapeutic uses of statins, as well as 




Chapter 5 Future Directions 
 
Currently, few studies have investigated the polarised secretion of ECs, or how this process 
is regulated. My study provides information about the proteins which are secreted, and 
whether they are secreted from the apical or basolateral surface of ECs. As expected, the 
secretion of many ECM proteins such as perlecan were found to basolaterally polarised.  
In order for the secretion to be polarised within the EC, the protein must have previously been 
sorted to the correct surface. There is currently limited information about the mechanisms 
involved in the polarised sorting of these proteins, however, a previous study has highlighted 
a mechanism involving the protein liprin-α1 has been shown to be involved in the sorting of 
fibronectin [35]. Fibronectin is a known component of the extracellular matrix which underlies 
endothelial cells, which I showed in my early analysis was basolaterally polarised. My data 
from my ELISA provides some evidence that liprin-α1 is involved in the secretion of FN from 
the basolateral surface. However, the fact I was coating my Transwell with FN, and the small 
change in secretion observed in my mass spectrometry data means further investigation is 
required. 
Successfully culturing HUVEC can be difficult, and studies have shown that HUVEC have a 
higher proliferation rate when cell plates are coated with ECM substrates prior to cell seeding 
[227]. The culturing of HUVEC in our lab had been shown to be most successful when plastic 
culture dishes were coated with FN, and when Transwell inserts were coated in a triple coat 
of human FN, bovine collagen, and bovine gelatin.  
When studying the effect of liprin-α1 depletion and statin treatment of HUVEC, my Transwells 
were each coated with this triple coat. Due to the cell culture substrate containing human FN, 
there is a possibility that the amount of FN secretion I recorded, both using ELISA and mass 
spectrometry may be inaccurate. The cell culture substrates also included bovine gelatin and 
collagen. Whilst I removed non-human contaminants from my mass spectrometry data during 
analysis, there is a possibility that this may have affect EC secretion, and the results found in 
my study would not be replicable without these substrates using for coating, and hence in vivo. 
However, due to time limitations, it was not possible to test and validate different methods for 
successfully culturing HUVEC.  
The dysregulated secretion of fibronectin is known to be a contributing factor in the 
progression of atherosclerosis. In my study I aimed to find out whether depleting liprin-α1 
affected the secretion of any other proteins. The depletion of liprin-α1 affected the 
apical/basolateral secretion of a subset of proteins, which could suggest liprin-α1 is involved 
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in the sorting of these proteins, the proteins are trafficked along with FN, or the proteins were 
compensating for the decreased FN secretion. To make my results more robust and to ensure 
I had identified correct proteins, I would repeat my mass spectrometry and perform ELISAs of 
the conditioned media. I could also examine if any of these proteins affected are involved in 
the formation of an atherosclerotic plaque, as this could provide further insight into the 
pathogenesis of atherosclerosis. For some of the proteins identified, the overall secretion 
decreased when liprin-α1 was depleted within HUVEC. A further investigation for these 
proteins could involve staining for the particular protein, to identify if it had accumulated within 
the cell.  
For the next part of my study, I explored the effects of two statins upon HUVEC. Statins are 
currently one of the most commonly prescribed drugs in the UK, with factors such as an ageing 
population, increasing rates of obesity and increasing rates of heart disease, the number of 
statins prescribed is undoubtedly going to rise over the coming years. Whilst statins are well 
known for their plasma cholesterol lowering properties by inhibiting HMG-CoA reductase, 
there is widening interest into pleiotropic effects statins may have, especially in ECs. In my 
study, I focussed upon the effects of statins on ECs, and specifically the effect on the polarised 
secretion of proteins.  
Throughout my study I experienced various limitations. The simvastatin powder used in my 
experiment had a 98% purity and the atorvastatin had a purity of 99.93%. Therefore, I cannot 
be certain whether the effects were a direct effect of the statin treatment, or whether the 
impurities in the sample affected this in any way. Repeating this experiment with a purer 
simvastatin sample would provide more accurate results, which could provide further insight 
into the proteins affected. 
During the preparation for the mass spectrometry, the 5 nM atorvastatin treated HUVEC 
sample was lost, and I used a sample from a previous experiment. However, after comparing 
the results of the replacement 5 nM sample to the samples at other atorvastatin doses, I 
concluded the results were incomparable and could not be used. This reduced my ability to 
see relationships between the dose of statins and the polarised secretion ratios, meaning I 
could have missed some proteins which would have showed relationships. To continue this 
study, I would need to repeat this experiment with a 5 nM sample to fully investigate any effect.  
After this, western blots could be performed on the proteins indicated within the mass 
spectrometry to measure their expression. I could then use methods such as 
immunofluorescence to examine whether treatment with statins affected their location within 
the cell, in comparison to cells which had not been treated with statins. These proteins could 
also be depleted using CRISPR/cas9 to further study the role of the protein within ECs.  
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As all my current work has involved using HUVEC, the use of other cell lines could provide 
further validation, for example using human coronary artery endothelial cells (HCAEC). Using 
these cells may be more physiologically relevant, as atherosclerosis primarily occurs within 
the coronary arteries. Therefore, it would be interesting to see whether the same changes in 
polarised secretion were observed. 
HUVEC have been shown to have sex differences [228]. As males have a higher risk of 
developing cardiovascular disease than women, I could use single donor HUVEC with a 
known sex to see whether the effects in male HUVEC differed from those in female HUVEC. 
These steps would improve the clinical validity of my results and could aid future studies into 
these effects. I could also expand the range of statins, examining the effects of the other 
common statins within the UK, such as pravastatin and rosuvastatin. This would allow me to 
analyse whether the effects seen could be generalised across all statins, or whether they were 
specific to particular statins. 
There have already been some studies into effects of statins on EC function in apoE-/- mice, 
which have shown statins have a positive effect on ECs in vivo, such as promoting eNOS 
function, and enhancing the response to the vasoconstrictive ET-1 in the aorta [229,230] 
However, many of these studies have used concentrations well beyond those used for human 
treatment. Throughout my study I used clinically relevant concentrations of statins to 
investigate the effect on protein secretion. If my results were repeated and verified, these 
concentrations could be investigated in apoE-/- mice to provide more clinically valid results. 
As currently there are few studies into the methods of protein sorting for polarised secretion, 
further studies would be needed in order to elucidate these methods, before investigations 
into changes in this pathway could be performed. These further suggestions and 
improvements would build a more solid basis for my results and could possibly indicate other 
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